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Angiogenesis, an essential process in wound healing and tumor growth, also 
represents a therapeutic target for tissue repair. Its inherently complex 
nature requires participation of multiple chemokines and also the crosstalk 
between endothelial cells (EC) and other cell types. This process was studied 
in a microfluidic platform that allows endothelial cells (EC) to migrate out 
from a monolayer then invade into a collagen gel up a gradient of factors 
secreted by a pool of encapsulated fibroblasts. Prolyl hydroxylase inhibitor 
(PHi) that can prevent the degradation of hypoxia inducible factor-1 (HIF-1α) 
primarily in fibroblasts induced sprouts formation in EC, but the most 
complex vascular networks with true lumina were achieved after pairing PHi 
with the signaling sphingolipid, sphingosine 1-phosphate (S1P). I have 
demonstrated that a cross gradient of mutually stimulating factors was 
generated as each cell type responded differently to the compounds, 
especially to the PHi. EC showed increased secretion of placental growth 
factor, endothelin-1, epidermal growth factor and interleukin-8 while 
fibroblasts showed upregulated secretion of hepatocyte growth factor, 
insulin-like growth factor-binding protein 2, urokinase plasminogen activator 
and most importantly, vascular endothelial growth factor (VEGF). I also 
showed that S1P induced migration was S1P receptor 1 (S1P1) dependent 
and more importantly the expression of S1P1 on EC could be modulated by 
both PHi and S1P. The downregulation of either VEGF or S1P1 showed 
attenuated capillary sprouting and also change of sprouting morphologies. 
The proangiogenic monocyte chemotactic protein (MCP)-1 was mainly 
secreted by fibroblasts, but only in the presence of EC-conditioned medium 
(CM). Antibody interference with MCP-1 also reduced the sprouting response. 
The EC-fibroblast interactions could be replaced by neither fibroblast CM nor 
EC-lung carcinoma crosstalk. These observations not only confirm the 
importance of EC-fibroblast crosstalk in angiogenesis but also suggest that 
the combination of PHi and S1P enhances this effect and thus might be of 
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 CHAPTER 1. INTRODUCTION 
 
1.1 Problem Statement 
Angiogenesis has been implicated in more than 70 disorders affecting more 
than one billion people worldwide [1, 2]. The consequences of either too 
much or too little angiogenesis are reflected in various world leading causes 
of deaths including cancer and ischemic heart disease. Consequently, there 
has been search of ways to control angiogenesis for decades but none is 
successful so far. This depicts the fact that vascularization is a much more 
complex process than expected and this is the reason why conventional 
therapies that deal with either one or few angiogenic factors fail. The 
strategies for promoting vascularization are not only significant for 
therapeutic angiogenesis but they also lay ground for discovering effective 
approaches against unregulated vascularization such as the vascularization in 
tumor growth. Furthermore, insufficient vascularization has always been a 
key limitation in tissue engineering which leads to its unavoidable failure [3]. 




Prolyl hydroxylase inhibitors (PHis) possess both angiogenic and antifibrotic 
effects and this fortunate combination has been demonstrated in human cell 
cultures and transgenic zebrafish [4]. Inhibition of prolyl hydroxylase results 
in stabilization of hypoxia inducible factor-1α (HIF-1α) and promoting 
transcription of over 70 target genes, including VEGF and its receptor, 
VEGFR1, hence, an angiogenic cascade will be triggered [5]. Similarly, 
sphingosine 1-phosphate (S1P) has been shown to modulate angiogenesis in 
various aspects including cell proliferation, cell migration and vasculature 
permeability [6, 7]. It has also been shown that HIF and S1P could each affect 
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the other but the exact mechanism and their causal relationship still remain 
unclear [8]. Therefore, I hypothesize that the combination of these two 
compounds might indeed be effective in inducing angiogenesis through their 
multiple actions. 
The importance to include a second cell type such as fibroblasts to enhance 
angiogenesis has been well documented and previously I have also shown 
that PHis exert greater effect in stabilizing HIF-1α expression in fibroblasts as 
compared to endothelia [4]. However, the current in vitro human cell culture 
represents a 2D system which is not an ideal platform for studying 
angiogenesis especially when I need to include a second cell type in the 
studies. Consequently, microfluidic devices that can accommodate multiple 
cell type at ease are used as they can offer great control over solute 
concentration gradients and can allow the growth of capillary sprouts from 
an endothelial monolayer into 3D collagen gel scaffold. 
 
1.3 Objectives 
The main goal of this project is to study the combinatorial effects of PHi and 
S1P induced angiogenesis in the presence of fibroblasts as mediating cells by 
using a microfluidic platform. 
 
1.4 Dissertation overview 
PHis and S1P have been shown to promote angiogenesis independently but 
their combined effects have yet to be tested. The beneficial effects of 
fibroblasts in maintaining capillary sprouts and the advantages of using 
microfluidic platform to study angiogenesis have been discussed previously in 
literature [9]. Nonetheless, this is the first study that combines PHis and S1P 
to induce angiogenesis in a fibroblast populated microfluidic platform. I not 
only look into the morphological development brought by PHis and S1P but 
also try to find out their effects on endothelia and fibroblasts. With the help 
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of microfluidics, I could also appreciate the importance of endothelia-
fibroblast interactions, especially in the presence of PHis and S1P. I set off to 
discover new strategies for therapeutic angiogenesis while the knowledge 
that I have contributed also help to understand the effects of hypoxia or S1P 
in a wound healing context. 
In the following chapters I will discuss: 
 the detailed features of the microfluidic platform that I used and also 
the validation of such platform in studying angiogenesis 
 
 the selection of PHis based on their potency in inducing angiogenesis. 
Ciclopirox olamine (CPX) was selected and combined with S1P and in 
combination, these compounds could induce a complex vascular 
network with lumen in a 3D collagen matrix 
 
 the effects of CPX in enhancing the secretion of differential and 
complementary angiogenic proteins from both endothelia and 
fibroblasts. I have also demonstrated that VEGF secreted by 
fibroblasts can be further enhanced by CPX. The interference of VEGF 
not only attenuates the capillary formation but also changes the 
morphologies of sprouts 
 
 the pro-migratory effects of S1P on endothelial cells is mediated 
through the S1P1 receptor. Expression of S1P1 could be affected by 
both CPX and S1P. Inhibition of S1P1 leads to reduced capillary sprouts 
and also affects the diameter and tip cell formation of sprouts 
 
 the indispensable effects of endothelia-fibroblast crosstalk where 
endothelia could communicate with fibroblasts and lead to 
upregulation of proangiogenic cytokine, monocyte chemotactic 
protein (MCP)-1. The neutralization of MCP-1 also reduces sprout 
formation. The importance of the crosstalk was further demonstrated 
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through conditioned medium (CM) experiment and also by 
substituting fibroblasts with another cell type 
Combined, this thesis has contributed to the first application of PHi and S1P 
in inducing angiogenesis. This thesis has also demonstrated the importance 
of fibroblasts in mediating angiogenesis in an in vitro microfluidic platform for 
studying angiogenesis.  
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 CHAPTER 2. BACKGROUND & 
LITERATURE REVIEW 
 
2.1 Basis of angiogenesis 
Angiogenesis is the growth of new blood vessel from a pre-existing one [10]. 
This growing process is usually quiescent in adult and will only be activated 
during wound healing, reproductive cycling or ocular maturation [11]. 
Angiogenesis is initiated by local increase of angiogenic stimuli, including 
vascular endothelial growth factor (VEGF), which would bind to specific 
receptors on endothelial cells (EC) of nearby pre-existing vessels thus 
activating EC to secrete various molecules and increase endothelial 
proliferation while also decrease cell-cell adhesion at the same time. 
Subsequently, the activated EC would lead to vasodilation and increase 
permeability of the pre-existing vessels in response to nitric oxide synthase 
and VEGF [11]. Following that, the basement membrane surrounding pre-
existing vessels would be either remodeled or degraded through the 
activation of matrix metalloproteinase (MMP)2, MMP3 and MMP9 and 
suppression of tissue inhibitor of metalloproteinase (TIMP)1 and TIMP2 [12, 
13]. The disturbed extracellular matrix (ECM) allows the activated EC to 
sprout forward easily. Sprouting angiogenesis is always led by a pioneer cell 
called tip cell which is responsible for the directional migration whereas stalk 
cells align and form a lumen behind tip cells [14]. The sprouts anastomose to 
connect with neighboring vessels and form a functional network that can 
circulate blood [10, 11].  
However, the sprouts formed at this stage are less stable and require the 
recruitment of mural cells and generation of ECM to stabilize them. In 
physiological conditions, functional and stable vessels are always covered by 
several smooth muscle cells (SMC) in the proximal part of larger vessels or 
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pericytes in smaller vessels to help regulate the proliferation and survival of 
EC [1, 15]. During the wound healing process, mural cells are recruited 
through several pathways: platelet derived growth factor (PDGF) B – PDGF 
receptor; Sphingosine-1-phosphate (S1P) – endothelial differentiation 
sphingolipid G-protein-coupled receptor-1 (EDG1 or S1P1); Angiopoietin 
(ANG)1 – Tie 2; and transforming growth factor (TGF)-β –TGF-β receptor II [11, 
16-19]. Once mural cells are recruited to the site of sprouts, they would start 
depositing extracellular matrix such as laminin and fibronectin followed by 
collagen I to allow attachment and adhesion of endothelium [20].  
Stromal cells around the capillaries such as fibroblasts are important for 
mediating angiogenesis where fibroblasts have been shown to control the 
capillary morphogenesis through complex spatiotemporal regulation of 
multiple angiogenic proteins including VEGF, Ang1, hepatocyte growth factor 
(HGF), fibronectin and MMP production and also through matrix remodeling 
[21-24]. Besides, angiogenesis also relies on cell-cell interactions such as 
endothelia-fibroblast interplays that depend on endothelin-1 secretion from 
endothelia [25]. Fibroblast-cardiomyocyte interplays also affect the secretion 
level of interleukin (IL)-6 and tumor necrosis factor-α (TNF-α) [26]. 
Inflammatory response is a concomitant mechanism to spur neoangiogenesis 
[27]. The increase of vascular permeability and EC activation is the first step 
in angiogenesis and this process is usually triggered by inflammation [28]. 
Various types of immune cells including neutrophils, T-cells, 
monocytes/macrophages, mast cells and dendritic cells have been shown to 
be able to secrete VEGF and other inflammatory cytokines such as IL-8 during 
a wound healing process [28, 29]. In particular, monocytes/macrophages 
have been shown to participate in angiogenesis actively through several 
pathways including the secretion of MMPs for vessel guidance, the activation 
of VEGFR3 on EC and also the recruitment of EC progenitor cell to the 
sprouting site [28]. From these studies, I can clearly see that angiogenesis is a 
highly complex biological event that requires the efforts and communications 




2.2 Angiogenesis implicated diseases 
In 2005, a comprehensive study on angiogenesis implicated disorders has 
been published by Fischer et al and the list that they compiled shows that at 
least 70 diseases affecting different organs such as cancers, psoriaris, diabetic 
retinopathy, arthritis and synovitis, inflammatory bowel disease and the 
world number one killer, coronary heart diseases are directly related to 
either excessive or insufficient angiogenesis [1].  In 2011, another list of 
disorders characterized by angiogenesis was compiled by Bhadada et al. Both 
studies are quite similar except that Bhadada et el. pointed out that certain 
kidney diseases are related to excessive angiogenesis such as end-stage renal 
disease, autosomal dominant polycystic kidney disease and chronic kidney 
disease which were missed out in previous study [30]. From the long list of 
diseases that are associated with angiogenesis, I could appreciate the 
importance of angiogenesis in various biological processes. Among the 
disorders that are mentioned in the two compiled list, ischemic conditions 
with insufficient angiogenesis in different parts of human body; and cancer 
with excessive angiogenesis in various organs are the two major diseases that 
draw the greatest attention and potential therapeutic approaches have been 
proposed.  In this thesis, I focus primarily on the factors that are 
proangiogenic. 
 
2.3 Therapeutic angiogenesis 
2.3.1 Protein therapy 
Therapeutic angiogenesis that targets ischemic tissue or chronic wound with 
insufficient angiogenesis has been widely studied. Generally, they can be 
divided into three major methods to enhance angiogenesis: protein therapy, 
gene therapy and cellular therapy [10]. Protein therapy, also known as 
growth factor therapy, is the most traditional method of therapeutic 
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angiogenesis. It uses purified growth factors such as VEGF or basic fibroblast 
growth factor (bFGF) to promote angiogenesis through different 
administration routes [31]. However, none of the protein therapy approaches 
have been approved by the FDA for treatment of any ischemic disorders. This 
is because phase II clinical trials based on recombinant human (rh)VEGF and 
bFGF did not show significant improvement in ischemic patients in terms of 
exercise tolerance test (ETT) and single-photon emission computed 
tomography (SPECT) [32, 33]. Over nearly a decade, no further clinical trial 
has been planned for protein based therapeutic angiogenesis due to the 
disappointing clinical trials mentioned above. The major reason contributing 
to the failure of protein therapy is the ineffective route of administration 
which leads to insufficient exposure time and concentration to the target 
tissue hence limiting its effectiveness [34].  
 
2.3.2 Gene therapy 
Gene therapy is another approach to therapeutic angiogenesis. There are two 
gene delivery techniques which are commonly used: plasmid or adenoviral 
vectors. The main benefit of using gene delivery over conventional protein 
therapy is the sustained release of therapeutic agents at target areas hence 
repetitive administration of therapeutic proteins is no longer required. Based 
on the compiled data from Zachary et al, gene therapies that focus on single 
VEGF gene activation have failed thus far [34]. Most recently, a phase II 
clinical trial on percutaneous intramyocardial transfer of bicistronic 
VEGF165/bFGF plasmid failed to show improvement on SPECT and only 
marginal improvement on ETT was observed [35]. Similarly, TAMARIS phase 
III clinical trial was carried out by Sanofi-Aventis where naked FGF-1 plasmid 
or also known as XRP0038/NV1FGF was tested in patients with critical limb 
ischemia but it was not found to reduce the rate of amputation as compared 
to the placebo control [36]. Nevertheless, there are still two ongoing phase I 
and phase III clinical trials that use VEGF-D and FGF-4 as their target genes, 
respectively. KAT301 is a phase I clinical trial that evaluates the possible 
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application of catheter mediated endocardial adenovirus VEGF-D gene in 
patients with myocardial infarction. AWARE, is another ongoing clinical trial 
that aims to reduce the time to onset myocardial ischemia in women with 
stable angina through the infusion of Ad4FGF-4 [34]. The major reason that 
impedes the efficacy of current gene therapy is the low transduction 
efficiency. The transduction efficiency is estimated to be around 5 -10 % by 
using the most effective vectors available to human [37]. 
 
2.3.3 Cellular therapy 
Cell-based therapies open up another possibility in the search of the 
solutions for therapeutic angiogenesis. Various cell types such as endothelial 
progenitor cells (EPCs), bone marrow-derived cell (BMCs), mesenchymal stem 
cells (MSCs), cardiac stem cells (CSCs), skeletal myoblasts, hematopoietic 
progenitors, cord blood cells, adipose cells, cardiomyocytes and embryonic 
stem cells (ESCs) have been studied for the feasibility to be infused into the 
recipients to promote angiogenesis. However, the translation of cell-based 
therapies from bench top to bed side has encountered various challenging 
issues and the results among different research groups are sometimes 
contradictory [38, 39]. The two main reasons that cause the variations 
between groups are: different processing methods in cell purification and 
unclear functions of various cell types in the process of angiogenesis. For 
example, EPCs that are cultured differently could lead to two distinct putative 
EPC populations: early EPCs and outgrowth endothelial cells (OECs). These 
two cell types show distinctive behaviors in terms of proliferation rate, cell 
surface antigens expression and morphology [40]. The differences in the 
cellular behaviors would affect the roles that they play during angiogenesis 
such as the early EPCs would secrete higher amounts of angiogenic peptides 
that contribute to paracrine effects while the donor OECs with higher 
proliferation rate might differentiate actively to form vessel lining in 
recipients [41]. In short, cellular based therapeutic angiogenesis remains 
attractive and numerous clinical trials that focus on BMCs, MSCs, CSCs and 
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EPCs are ongoing despite of the limited success of previous studies and 
various challenges such as the threat of forming tumors lay ahead. 
The conventional protein or gene therapies for therapeutic angiogenesis have 
been focusing on single protein administration or induction while these 
methods have so far been proven to be less effective in enhancing 
angiogenesis [32, 34]. Besides, angiogenesis is a complex process that 
involves accurate orchestration of various cytokines and molecules as 
discussed earlier hence the need for careful manipulation of various 
angiogenic factors arises. Prolyl hydroxylase domain (PHD) inhibitors or also 
known as prolyl hydroxylase inhibitors (PHis) could serve as a solution to 
current unmet clinical needs as PHis stabilize the master switch of hypoxia, 
HIF-1α.  This results in the simultaneous up-regulation of various angiogenic 
genes in a way similar to angiogenesis under hypoxic stress. To further 
strengthen the angiogenic effects, S1P that complements the actions of PHis 
through modulating multiple angiogenic processes such as endothelial 
migration, cell proliferation, mural cell recruitment and barrier protection can 
be combined with PHis to maximize their angiogenic potential [6].  
 
2.4 Hypoxia inducible factors (HIF)-1 
HIFs are heterodimeric transcription factors comprised of α and β subunits 
[42]. The α-subunit is degraded rapidly under normoxic conditions in an 
oxygen dependent manner while the β-subunit, HIF-1β (also known as aryl 
hydrocarbon receptor nuclear translocator, ARNT) is oxygen insensitive and 
constitutively expressed [42]. There are three different α-isoforms in 
mammalian cells: HIF-1α, HIF-2α and HIF-3α [43]. Although HIF-1α and HIF-2α 
share structural similarities, they have distinct spatiotemporal expression 
patterns and cellular functions and are regulated differently [44]. HIF-1α is 
believed to be the main regulator of vascular formation instead of HIF-2α, 
which is mainly responsible for regulation of renal Epo synthesis [44].  
Conversely, HIF-3α that lacks the C-terminal transactivation domain has been 
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reported to play a negative role in regulating HIF signaling and also 
angiogenesis [45, 46]. The expression of HIF-3α is cell type specific [47]. 
Endothelial cells express multiple splice variants of HIF-3α but only the 
expression of HIF-3α2 elevates during hypoxia [47]. Interestingly, another 
splice variant HIF-3α4 has also been shown to suppress angiogenesis in a 
brain tumor model [46]. Nonetheless, HIF-1α that is ubiquitously expressed 
still plays a dominant role in activating the downstream angiogenic cascade 
during hypoxia hence it will be the primary isoform that I focus on. 
Under normoxic conditions, the expression of HIF-1α is suppressed by prolyl 
hydroxylase domains (PHDs) and factor inhibiting HIF (FIH). Similar to α 
subunit of HIF, there are three PHD isoforms as well: PHD1, PHD2 and PHD3 
each having different regulatory functions to the α subunit of HIF-1. PHDs 
require oxygen to hydroxylate HIF-1α and their Michaelis-Menten constant, 
Km for oxygen is higher than the physiological oxygen concentration in tissue 
hence PHDs are highly sensitive to the change of oxygen concentration [44]. 
The proline residues at 402 and/or 564 of HIF-1α would be hydroxylated by 
PHDs into hydroxyproline in the presence of ferrous iron, ascorbic acid and 2-
oxoglutarate (2-OG) as co-factors or co-substrate when oxygen is available 
(normoxic conditions) [43]. The hydroxylated HIF-1α would then be 
recognized by von Hippel-Lindau tumor suppressor protein (pVHL) hence 
leads to the ubiquitination of HIF-1α followed by proteosomal degradation of 
it. This process is rapid as accumulated HIF-1α under hypoxic conditions can 
be degraded rapidly with a half-life of less than 5 minutes on reoxygenetion 
in vitro [48].  
By using PHis, the activity of PHDs will be attenuated even under normoxic 
conditions. Therefore, the hydroxylation of proline residues at 402 and 564 
can be prevented so that HIF-1α can escape from the proteosomal 
degradation pathway. The stabilized HIF-1α is then dimerized with the HIF-1β 
and translocate into nuclei to activate the transcriptions of downstream 
target genes. In short, PHis can be used to stabilize HIF-1α and to activate 
angiogenesis cascade under normoxic conditions.  
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On the other hand, FIH uses oxygen to hydroxylate HIF-1α under normoxic 
conditions too. Its Km is 3 three time lower than that for the PHD family and 
the hydroxylation site for FIH is asparagine residue, Asn 851 in HIF-1α or 
another similar Asn residue in HIF-2α. Once hydroxylated by FIH, HIF-1α 
would be prevented from interacting with p300/CBP, a transcriptional 
activator at the HRE [43]. Consequently, the hydroxylation of HIF-1α by FIH 
could severely reduce the transcriptional activity of HIF-1 and this mechanism 
is different from the destabilization effects of PHD family on the α subunit of 
HIFs. A schematic drawing of oxygen dependent-HIF regulation under either 
normoxic or hypoxic conditions is shown in Figure 2-1, adapted from Mole et 
al. [49]. There are several oxygen-independent controls of HIF signaling such 
as phosphoinositide-3 kinase (PI-3K), mitogen-activated protein kinase 
(MAPK), mammalian target of rapamycin (mTOR), nitric oxide (NO) and 
carbon monoxide (CO) but they are beyond the scope of this work hence will 




Figure 2-1 Oxygen dependent regulation of HIF signalling adapted from Mole et al. 
[49]. Under normoxic conditions, PHD family hydroxylate Pro402 and Pro564 residue 
in HIF-1α which leads to the recognition by pVHL and followed by the ubiquitin-
ligase binding and it will finally be degraded through proteosomal destruction. FIH 
also hydroxylate Asn 851 in HIF-1α and causes the reduced transcriptional activity 
through inhibition of binding of transcriptional cofactors p300/CBP binding. When 
oxygen concentration goes lower, the PHD and FIH activity would be inhibited hence 
HIF-1α dimerize with HIF-1β and bind to HRE of target genes which leads to 




2.5 Multiple genes are regulated by HIF-1 
As hypoxia regulates not only angiogenesis but also other functions such as 
glycolysis and cell proliferation, the target genes regulated by HIF are 
anticipated to be numerous. According to the gene profiling study that was 
done by Semenza group [5], whereby arterial endothelial cells were 
transfected with AdCA5 that encoded a constitutively-active form of HIF-1α. 
They have found that 245 gene probes show at least 1.5 fold increase under 
hypoxic conditions or being transfected with AdCA5 while 325 gene probes 
show at least 1.5 fold decrease in the same conditions [5]. As I am interested 
in the proangiogenic genes, a summary only of proangiogenic proteins 




Table 1 Hypoxia induced angiogenesis related proteins 
Protein Hypoxia Response References 
Angiopoietin-1 Increase/Decrease [51, 52] 
Angiopoietin-2 Increase/Decrease [51, 52] 
basic Fibroblast Growth Factor (bFGF) Increase [53] 
C-X-C chemokine receptor type  4 (CXCR-4) Increase [5] 
Endothelin-1 (ET-1) Increase [5] 
Epidermal growth factor (EGF) Increase [54] 
Flt-1 (VEGFR-1) Increase [55] 
Hepatocyte growth factor (HGF) Increase [56] 
Insulin-like growth factor binding protein 2 
(IGFBP-2) 
Increase [57] 
Insulin-like growth factor binding protein 3 
(IGFBP-3) 
Increase [5] 
Interleukin 8 (IL-8) Increase [58] 
Platelet-derived growth factor (PDGF-B) Increase [5] 
Placenta growth factor (PlGF) Increase [5] 
Stromal cell-derived factor 1 (SDF-1) Increase [59] 
Urokinase plasminogen activator (uPA) Increase [60] 
Vascular endothelial growth factor (VEGF) Increase [5] 
“Increase/Decrease” refers to conflicting data resulting from different studies. 
“Increase” refers to upregulation of protein expression/secretion under hypoxia     
 
2.6 Current Research Status of PHis 
PHis are proposed to be used as angiogenesis induction agents because PHis 
can effectively inhibit the activity of PHDs hence stabilize the HIFs and cause 
the up-regulation of HIF target genes under normoxic conditions. Various 
PHis have been studied and some of them are initially being used as 
inhibitors for collagen prolyl hydroxylase (CPH) to counter fibrosis. 
Hydralazine hydrochloride (HDZ), ciclopirox olamine (CPX) and 2,4-pyridine-
dicarboxylic acid (PDCA) are just a few examples  [4, 61, 62]. The uses of PHis 
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for ischemic and inflammatory disease have recently been reviewed by Fraisl 
et al. and are summarized in Table 2, adapted from Fraisl et al. [63]. 
 
Table 2 Selected list of inhibitors of PHD, adapted and modified from Fraisl et al. [63] 
PHi Principle of action Physiological effects 
Dimethyloxalylglycine 
(DMOG) [64, 65] 
Mimics 2-OG 
Promotes angiogenesis, confers hypoxia 






Confers hypoxia tolerance, ischaemic 
preconditioning 
L-Mimosine [68, 69] 




Promotes angiogenesis, anti-fibrotic 






interferes with cofactor 
Promotes secretion of VEGF 
FG-0041[71] 




Confers hypoxia tolerance 
FG-2229 (ciclopirox 
olamine, CPX) [71] 




Promotes angiogenesis, antimycotic 
FG-4497[72] Blocks active site 
Confers hypoxia tolerance, suppresses 
inflammation 
2,4-pyridine-dicarboxylic 
acid (PDCA) [4] 
Mimics 2-OG 
Reduces collagen deposition, promotes 
angiogenesis,  
GSK360A [73] Mimics 2-OG 
Improves ventricular remodeling and 
vascularization 





Promotes angiogenesis, ischaemic 
preconditioning 
TM 6008 [75] 




Promotes angiogenesis,  neutoprotective 
TM 6089 [75] Blocks active site Promotes angiogenesis 
Dealanylalahocin 
analogues [76] 
Block active site Not determined 
8-Hydroxyquinolines [77] Block active site Not determined 
Pyrazolopyridines [78] Block active site Not determined 
*2-OG: 2-oxoglutarate 
 
This list shows most of the PHis that are being actively investigated for 
applications in therapeutic angiogenesis. Among these, dimethyloxalglycine 
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(DMOG), desferrioxamine (DFX) and L-Mimosine (L-mim) are the three most 
widely studied PHis [68, 79, 80]. Their angiogenic properties have been 
shown in different models such as the mice femur fracture model and 
diabetic mice model [80, 81]. PDCA has been around as potent CPH inhibitor 
and has been shown to be effective in inducing in in vivo transgenic zebra fish 
model [4, 49, 82]. Interestingly, PDCA has been reported to be able to affect 
the epigenetic profile through disruption on 2-OG dependent JMJD2 
subfamily of histone demethylases [83]. Besides, GlaxoSmithKline (GSK, King 
of Prussia, PA) has developed GSK360A that competes with the 2-OG for the 
binding site on PHD family. The rat model shows that GSK360A could help 
improve ventricular performance, remodeling and vascularization, but the 
response is limited after myocardial infarction. That was the first animal 
model that studied the benefits of PHi post-myocardial infarction which is 
more clinically relevant in terms of treatment for myocardial infarction [73]. 
Of particular note are the PHis, TM6008 and TM6089, as they represent a 
novel class of PHis that have been identified through docking simulations to 
bind to PHD2 specifically [75]. Among these, TM6008 also acts as iron 
chelator hence its angiogenic potential and protective effects on cerebral 
ischemic injury (observed in a gerbil model) are much greater than TM6089 
but the latter still holds great potential as it has specificity towards PHD but 
not other co-substrates or co-factors, hence lower cytotoxicity is expected. 
Besides, pyrazolopyridines and 8-hydroxyquinolines are synthesized through 
structure-based design with the intention of increasing specificity to PHD2 
[77, 78]. Novel compounds with high specificity towards PHD2 are potential 
therapeutic agents with fewer unwanted side effects as compared to the 
conventional iron chelators or 2-OG analogs. Nevertheless, the properties of 
pyrazolopyridines and 8-hydroxyquinolines are not well characterized and 
more evidence needs to be gathered to prove their efficacy.  
Other than therapeutic angiogenesis, PHis have been studied as alternatives 
for treatment of chronic kidney disease and anemia. The AKB-6548 designed 
by Akebia Inc is a PHi that could stabilize HIF-2α hence increase natural 
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production of Epo in anemia patients. AKB-5448 is currently in a clinical 
phase II trial. On the other hand, Fibrogen Inc is the leading company in 
discovering novel PHis for different therapeutic purposes such as for anemia, 
myocardial infarction and fibrotic disease. FG4592 is one of the most 
successful PHis that could treat CKD anemia and is currently under clinical 
trial phase II [44]. 
Several 2-OG analogs have been patented by Schofield et al. and they 
showed that those 2-OG analogs can effectively modulate the activity of HIF 
prolyl hydroxylase [84]. Besides, researchers from the same group also 
patented those 2-OG analogs for the application in treating β thalassemia 
and sickle cell disease as those 2-OG analogs could increase the fetal 
hemoglobin production [85].  Gene therapies that target HIF pathway have 
also been patented by Semenza et al. and Arbeit et al. for the applications in 
therapeutic angiogenesis including enhancing wound healing and reducing 
the risk of ischemia-related tissue damage [86, 87]. However, the efficacy of 
gene therapies is limited by current technology as mentioned earlier [37].   
 
2.7 Sphingosine 1-phosphate 
S1P is formed through the phosphorylation of sphingosine by sphingosine 
kinase 1 and 2 (SphK1 and SphK2). The physiological balance of S1P is 
maintained by SphK1 and SphK2 and S1P-targeted enzymes such as S1P lyase 
(SPL) and S1P phosphatase [88]. Predominantly, S1P governs multiple 
biological processes including immune response, cell proliferation and 
angiogenesis mainly through engaging specific cell surface G-protein coupled 
receptors (GPCRs), S1P1-5 [89, 90]. The receptors are ubiquitously expressed 
but they have different expression profiles in different cells which allow S1P 
to modulate multiple physiological processes [91]. For example, S1P1 plays an 
important role in trafficking of immune cells where CCR7 deficient T cells 
egress from lymphoid organs more rapidly when treated with FTY720, an 
agonist that causes internalization of S1P1 [92].  S1P4 has also been shown to 
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play a role in neutrophil trafficking and inflammation in an S1P lyase-deficient 
mouse model where S1P is prevalent [93].  S1P5 is another receptor that has 
been associated with the egress of natural killer cells from lymph nodes and 
bone marrow [94]. 
S1P and S1P receptor interactions are also particularly important in vascular 
tone and angiogenesis. In particular, S1P1, S1P2 and S1P3 are three major 
receptors in blood vessels where loss of function of S1P1, S1P2 and S1P3 
causes embryonic lethality due to vascular abnormalities [95]. S1P1 and S1P3 
have been suggested to mediate S1P induced endothelia proliferation and 
migration in a p38 MAP kinase dependent manner [96, 97]. Moreover, S1P1 
and S1P3 activation would also lead to Rho-dependent integrin activation 
which favors the endothelial migration [98]. S1P1 is the main receptor that 
mediates angiogenesis [99]. Its ligand S1P reduces endothelial permeability 
through activation of protease activated receptor -1 (PAR-1) thus increasing 
endothelial barrier integrity [100]. In addition, a S1P1 specific antagonist was 
demonstrated to abrogate VEGF-induced angiogenesis in a cornea model 
[101]. In contrast, the functions of S1P2 in angiogenesis remain unclear as 
conflicting studies indicate both pro-angiogenic and anti-angiogenic effects of 
S1P2 [102, 103]. S1P3 also mediates endothelial nitric oxide synthase (eNOS) 
and nitric oxide production in endothelia which leads to vasodilation [104]. 
It has long been speculated that S1P not only exerts its effects through 
extracellular receptor signaling but it also serves as an intracellular 
messenger. Not until recently though, has it been elucidated that S1P and 
sphingosine are present in nuclei and the S1P produced in nucleus also 
affects the balance of histone acetylation through inhibition of histone 
deacetylase (HDAC) 1 and HDAC2 [105]. Its other functions as intracellular 
messenger such as regulating mitochondrial assembly together with its 
extracellular signaling roles make S1P a powerful signaling molecule that has 
implications in multiple diseases including Alzheimer’s disease, 
atherosclerosis, myocardial infarction and multiple sclerosis (reviewed in 
[88]). In particular, the research of S1P on multiple sclerosis has been most 
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successful and FTY720 that causes internalization of S1P1 has been approved 
by the FDA as a first line treatment for relapsing multiple sclerosis [106]. 
Besides, LX2931, a S1P lyase inhibitor, is currently in a phase II clinical trial for 
treatment of active rheumatoid arthritis. These show the potential of 
modulating S1P in affecting pathological conditions including angiogenesis 
related diseases. 
S1P and lysophosphatidic acid (LPA) have been patented for the applications 
in implantable medical devices by Astafieva et al. and Trollsas et al. [107, 108].  
As claimed in these patents, S1P and LPA can be used to coat the implantable 
medical devices including stents and act as chemo-attractants for endothelial 
cells to help improve healing effects. In addition, Elbert et al. have patented 
the use of S1P and sphingosine kinase in biomaterials such as polyethylene 
glycol (PEG) hydrogel to improve the recruitment of endothelial cells to the 
wound site [109]. Furthermore, S1P has also been patented for the use in 
bio-interface membrane , between biosensor and tissue, to help forming 
vascularization around an analyte sensor system such as blood glucose sensor 
for more accurate measurement of the analytes [110].   
As mentioned earlier, S1P is a multi-function signaling molecule which also 
plays a role in HIF-1 activity. Interestingly, SphK1 that is responsible for the 
production of S1P is also found to be upregulated during hypoxia. However, 
the mechanism of this is still unclear as Ader et al. suggested SphK1 is an 
upstream regulator to HIF-α and it could stabilize HIF-α through the pVHL 
pathway while Anelli et al. suggested the opposite, showing that SphK1 is the 
downstream target of HIF [111, 112]. This opens up a new territory in cancer 
research where strategies that inhibit S1P or SphK1 could also interrupt HIF-1 
activity. For example, FTY720 has been shown to inhibit S1P and VEGF 
induced angiogenesis and also tumor cell proliferation and apoptosis [113]. 
Nonetheless, the combined effects of HIF-1 activity and S1P signaling for 




2.8 Angiogenesis in Microfluidic Systems  
Recently, the study of angiogenesis has been extended into microfluidic 
platforms where control of flow, 3D cell culture environment, solute 
concentration gradients and real time observation of sprout formation could 
be realized. All these beneficial features of microfluidic devices are not 
readily available in conventional 2D cell culture or in animal models. For 
example, a way to determine the angiogenic potential of PHis is through its 
induction of capillary like structures (CLS) in endothelial cell-fibroblast co-
culture. In this case, endothelial cells are seeded on top of fibroblasts where 
elongated structures of endothelial cells on 2D are referred as CLS [4]. 
However, CLS is not an optimum way to study angiogenesis as this does not 
occur in vivo during angiogenesis. Microfluidic devices serve as an alternative 
in vitro system with added benefits to help understand angiogenesis and 
possibly help screen potential angiogenic agents before application in animal 
models. Besides, microfluidic devices could also provide other unmatched 
advantages such as the real time observation of sprout formation and greater 
control over solute concentration gradients. Consequently, microfluidics is 
adopted as a platform to study PHis and S1P induced angiogenesis in the 
present study.  
Vickerman et al. utilized microfluidic devices with two channels and a 3D 
collagen gel scaffold, for the study of sprouting angiogenesis in human adult 
dermal microvascular endothelial cells (HMVECs) under the effect of shear 
stress, and interstitial flow. They showed that HMVEC first migrated in 2D 
collectively and then formed tube-like structures in 3D collagen scaffold [114].  
Chung et al. also utilized microfluidic devices with three independent 
channels and showed that HMVEC could response differently by co-culturing 
with different cancer cell types. They also studied the effects of different 
collagen gel stiffness on HMVEC sprouting angiogenesis and found that stiffer 
matrices would inhibit the migration of HMVEC but also simultaneously 
helped the formation of thicker tube-like structures [115]. These previous 
studies revealed that HMVEC usually migrate collectively in 2D prior to the 
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formation of sprouts, hence Chung et al. further improved the microfluidic 
cell culture technique by application of PDL surface coating before the filling 
of collagen (Figure 2-2). This allows the formation of sprouts in 3D from a 
pre-formed endothelial cell monolayer which highly resembles the in vivo 
conditions [116].       
 
Figure 2-2 Schematic drawings of microfluidic device adapted from Chung et al.[116] 
The growth factor in condition channel induces HMVEC invasion into the 3D gel 
scaffold in a two-channel microfluidic platform. PDL pre-treatment solves the issue 
of collective cell migration in the microfluidics. 
 
Sudo et al. demonstrated that microfluidic devices could be used as a 
platform to study the interactions between primary rat hepatocytes and 
endothelial cells. They successfully grew hepatocytes into a tissue-like 
structure through the manipulation of interstitial flow and they also showed 
that rat endothelial cells were greatly induced by hepotocytes thus forming 
stable sprouts across the 3D collagen gel [117]. Shin et al. subsequently 
showed that orchestration of ANG-1 and VEGF gradients spatiotemporally 
could help prevent the regression of sprouts as compared to the induction by 
VEGF gradients alone. As a result, the number of tip cells that remain 
attached on stalk cells increased with the stabilization effect provided by 50 
ng/ml of ANG-1 [118]. Most recently, Kim et al. demonstrated the angiogenic 
potential of fibroblasts encapsulated in alginate beads for co-culture with 
HUVEC in microfluidics. They showed that VEGF production is dependent on 
cell encapsulation density which then affects the capillary sprouting [9].  
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Other than the above-mentioned microfluidic devices that were developed 
using a similar 3D collagen gel concept, several other strategies have been 
explored to study angiogenesis in 3D. Cardiac fibroblasts have been proven to 
be inhibitory to angiogenesis through contact-dependent mechanism in fibrin 
gel assays performed by Nehls et al. They coated endothelial cells and 
fibroblasts onto microcarrier beads before embedding them into fibrin gel 
and the angiogenesis process was observed in 3D subsequently [119]. The 
microcarrier bead technology is incorporated into a microfluidic device by 
Shamloo et al. by pre-coating endothelial cells onto microcarrier beads and 
then embedding the beads into 3D collagen matrix inside a microfluidic 
device with source and sink channels. Consequently, the concentration 
gradient of VEGF could be well established in the devices and they also 
confirmed that higher matrix density could increase the stability of lumen 
formation under the induction of a VEGF gradient [120]. In a similar setting, 
the authors further demonstrated that VEGF gradient induced-endothelial 
pathfinding in capillary sprouting is extracellular matrix-dependent [121]. 
Nguyen et al. developed a microfluidic platform that could accommodate a 
collagen type I matrix with two cylindrical voids inside the matrix [122]. They 
cultured endothelia in one void and applied angiogenic cocktails in another 
void. The cocktails consist of selections of angiogenic compounds from basic 
fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), VEGF 
monocyte chemotactic protein-1 (MCP-1), sphingosine-1-phosphate (S1P), 
and phorbol 12-myristate 13-acetate (PMA). These angiogenic cocktails could 
elicit capillary sprouting that travelled across the 3D collagen gel with lumina 
structures. In another study, Kim et al. utilized microfluidic platform that 
allows co-culture of endothelia and fibroblasts to study angiogenesis and 
vasculogenesis in a collagen I enriched fibrin matrix. With these setups, they 
were able to form perfusable vascular network that allows studies of flow 
induced responses and also stromal cell interactions with vasculature in vitro 
[123]. This was the first report on formation of perfusable networks in in vitro 
system through angiogenesis and vasculogenesis which were different from 
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previously reported perfusable networks that were formed through 
endothelial lining on structural supports [124, 125]. 
There are other interesting microfluidic designs that help to elucidate the 
endothelial cells behaviors. Barkefors et al. designed a microfluidic 
chemotaxis chamber (MCC) with three independent inlets that are connected 
at the downstream hence steady concentration gradients could be achieved. 
By using this design, they showed that endothelial cells migrate up VEGF 
concentration gradients and they also proposed that endothelial cells would 
turn into a non-migratory phenotype at the high end of the gradient [126].  
 
 
Figure 2-3 Schematic drawings of microfluidic devices, adapted from Nguyen et al. 
and Barkefors et al. [122, 126]. (A) Microfluidic device with two cylindrical voids 
inside a collagen gel matrix for growing capillary sprouting from one void to the 
other [122]. (B) Three-inlet design used to study the VEGF chemotaxis in endothelial 
cell migration [126]. 
 
Certainly, there are unmet clinical needs in therapeutic angiogenesis 
especially in critical limb ischemia, myocardial infarction, stroke and diabetic 
ulcers. From the relatively unsuccessful translation of protein therapy and 
gene therapy to clinical applications, I learn that the manipulation of one 
growth factor is insufficient to activate the complex angiogenesis cascade 
[127]. Consequently, PHis that can regulate multiple angiogenic genes 
through the stabilization of HIF-1α can be coupled with multi-action signaling 
lysophospholipid, S1P as a new strategy for therapeutic angiogenesis. As 
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angiogenesis requires an interplay between different cell types such as 
endothelial- fibroblast crosstalk, the need to study PHis + S1P induced 
angiogenesis in a co-culture platform arises. In order to accommodate 
multiple cell types while maintaining the ability to visualize capillary 
sprouting under the induction of PHis+S1P, I choose a microfluidic platform 




 CHAPTER 3. METHODS 
 
3.1 Cell Cultures 
Human umbilical vein endothelial cells (HUVEC), isolated from umbilical cord 
(kindly provided by Dr. Jerry Chan, National University of Singapore, 
Singapore), were plated in cell culture flasks that had been coated with 50 
µg/ml rat tail collagen I solution (BD, Bedford, MA) in 0.02 M acetic acid 
(VWR, PA) for 30 min, and maintained in EGM-2mv (Lonza, Walkersville, MD) 
until they were 80 % to 90 % confluent. IMR-90 human lung fibroblasts and 
A549 human lung carcinoma epithelial cell line were obtained from ATCC 
(Manassas, VA) and maintained in culture medium, DMEM (Gibco, NY) 
supplemented with 10 % fetal bovine serum (Gibco, NY) and 1 % Penstrep 
(Gibco, NY). All experiments were carried out with HUVEC at passages 5 to 6 
and IMR-90/ lung carcinomas at passages 16 to 18. Cultures were kept at 
37 °C in a humidified incubator with 5% CO2. As previously reported, the 
amounts of VEGF secreted by fibroblasts correlate directly with the 
concentration of encapsulated fibroblasts [9]. In this study, solutions 
containing 25 million fibroblasts / lung carcinomas per ml were used. 
 
3.2 Preparation of PDMS Microfluidic Device 
Microfluidic devices are fabricated from polydimethylsiloxane (PDMS) 
comprised of two gel regions and three cell seeding channels with two bead 
traps to contain alginate beads (Figure 3-1). The microfluidic devices were 
fabricated using standard soft lithography as described earlier [9]. In short, 
PDMS was poured onto an SU-8 master mold and cured for 4 h at 70 °C 
before peeling, trimming and punching holes into features as shown inFigure 
3-1. PDMS devices were autoclaved to ensure sterility and then bonded to 
cover slips (VWR, PA) after plasma treatment for 90 s (Femto Science, Korea) 
to render the hydrophobic surface hydrophilic and facilitate adhesion. 
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Microfluidic devices were immediately treated with 1 mg/ml Poly-D-lysine 
(PDL) solution (Sigma, St Louis, MO) for at least 4 h to enhance cell 
attachment as well as to prevent leakage of collagen gel during the gel filling 
step. The PDL treated microfluidic devices were then washed twice with 
filtered DI water and then kept in an oven (72 °C) for 48 h to return the PDMS 
devices to their hydrophobic nature and to evaporate any remaining water. 
Prior to cell seeding, collagen type I was injected into the devices through the 
collagen filling port (Figure 3-1). Once polymerized (1 h at 37 °C), collagen type 
I served as 3D scaffold for endothelial cells to grow into a capillary-like 
network. The devices are ready for cell culture after rehydration with culture 
medium in the channels. 
 
Figure 3-1 Detailed design of microfluidic device. The device comprises three culture 
media channels that allow culturing of multiple cell types, and two independent 
collagen gel regions intercalate between the three media channels. The width of the 
central channel is 1.2 mm and it is connected to two opening ports with 4 mm 
diameter. The side channels each have two rows of square posts with 70 µm spacing 
that act as bead trap regions to retain cells encapsulated or empty alginate beads in 
the channel. There are 7 cylindrical posts in the side channel with 300 µm diameter 
act as supportive pillars to prevent the channel from collapsing due to larger area of 
side channels. The collagen gel region is divided into 6 observation regions by 
trapezoidal posts that are spaced 110 µm apart and the width of gel region is 1.25 




3.3 Cell Seeding  
HUVECs were trypsinized and centrifuged at 200 g for 5 min and then 
resuspended in EGM-2mv at 2.5 M cells/ml. Media ports were then emptied, 
and 60 µl of HUVEC cells suspension was added into the center channel.  
Media were changed after 4 h to remove unattached cells from the channel. 
Microfluidic devices were incubated overnight at 37 °C to allow the formation 
of HUVEC monolayer that covered the collagen gel region. Subsequent cell 
cultures in microfluidic devices were static.  
 
3.4 Cell Encapsulation 
Fibroblasts were encapsulated in alginate beads as described earlier [128]. 
Briefly, 1% (w/v) alginate solution was made by dissolving 1 g of sodium 
alginate (Sigma, St Louis, MO) in 10 ml of culture medium. Fibroblasts were 
suspended in 1% alginate solution at 25 M cells/ml and then the suspension 
was passed through a two-phase microencapsulation device where alginate 
was calcified by calcium enriched oleic acid thus forming alginate beads 
containing fibroblasts. The beads were then injected into the right channel of 
endothelial cell-seeded microfluidic devices through the bead-inlet by 
micropipette. Injection through bead-inlet was necessary to contain beads 
within the bead trap region of the microfluidic devices. Similar procedures 
were used to encapsulate A549 lung carcinoma epithelial cells. 
 
3.5 Preparation of Conditioned Medium (CM)  
CM of endothelial cells was prepared by conditioning EGM-2mv with 83 k 
cells/ml (comparable to the cell concentration in the microfluidic device) 
HUVEC in 6-well plate over 24 h and the collected medium was centrifuged to 
remove cells and then used to culture fibroblasts in 6-well plates without 
further concentration or dilution. 
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CM of fibroblasts was prepared by conditioning EGM-2mv (Lonza, 
Walkersville, MD) with 100 k cells/ml IMR-90 in a 6 well plate over 24 h and 
then the CM was concentrated through dialysing with a 3 kDa filter (Millipore, 
MA). The concentrated CM was then diluted with EGM-2mv to reconstitute 
into concentration comparable to concentration in microfluidic devices. 
 
3.6 Selection of PHis 
Previously, works have been done on PDCA, HDZ and CPX and these three will 
remain the main study agents as PDCA shows promising angiogenic effects in 
in vivo model. Besides, both HDZ and CPX are FDA approved drug and are 
used as vasodilator and anti-mycotic agent respectively. 
 
3.7 Preparation of Prolyl Hydroxylase Inhibitors, 
S1P and VEGF 
Since angiogenesis is a highly complex biological process that requires 
participation of multiple angiogenic proteins, PHis that could upregulate 
various angiogenic cytokines through HIF-1α stabilization are of great interest 
for therapeutic angiogenesis [127]. Previously, our group demonstrated that 
ciclopirox olamine (CPX), hydrochloride hydralazine (HDZ) and 2,4-
pyridinedicarboxylic acid (PDCA) were able to induce angiogenesis either in 
2D cell culture or zebrafish models [4]. Therefore, these three PHis were 
selected to test for their angiogenic potencies in microfluidics. The working 
concentrations of these three PHis were determined through previously 
reported values from our group [4].   
Ciclopirox olamine, CPX (Sigma, St. Louis, MO) stock solution was made in to 
0. 5M by dissolving 67 mg of CPX in 500 µl of methanol. Stock solution was 
further diluted into 500 µl of culture medium to make yield 1 mM. CPX was 
used at 8 µM to stimulate angiogenesis. Hydralazine hydrochloride, HDZ 
(Sigma, St. Louis, MO) stock solution was made by dissolving 19.7 mg of HDZ 
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into one ml of filtered DI water at room temperature to yield 100 mM. 2,4-
pyridine-dicarboxylic acid, PDCA (Sigma, St. Louis, MO) powder (110 mg) was 
dissolved in 2 ml ultrapure water together with 120 mg of sodium 
bicarbonate (Sigma, St. Louis, MO) to form 300 mM  solution of 2,4-pyridine-
dicarboxylate through acid-base reaction. For simplicity, 2,4-pyridine-
dicarboxylic and 2,4-pyridine-dicarboxylate will be used synonymously as 
PDCA throughout the report. 
S1P powder (Sigma, St. Louis, MO) was added in methanol:water (95:5) to 0.5 
mg/ml, then sonicated at 45 °C until S1P was suspended in the solution. The 
solvent was removed by using a stream of dry nitrogen until a thin film of S1P 
formed and then stored at -20 °C as stock.  Fatty acid-free BSA (Sigma, St. 
Louis, MO) with a minimum concentration of 4 mg/ml was used as the S1P 
carrier to make 125 µM solution. The final concentration of S1P in culture 
media was 250 nM. Recombinant human VEGF165 (R&D, MN) was 
reconstituted at 100 µg/ml in sterile PBS containing 0.1 % BSA (Sigma, St. 
Louis, MO). 
 
3.8 Preparation of Avastin, Gefitinib, W146 and 
MCP-1 neutralizing antibody  
A 25 mg/ml stock solution of Avastin (Roche, Switzerland) was diluted with 
media into 0.1 mg/ml. human IgG (GenScript, NJ) was dissolved in recipient 
(240 mg of α,α-trehalose dehydrate (Sigma, St. Louis, MO), 23.2 mg of 
monobasic, monohydrate sodium phosphate (Sigma, St. Louis, MO), 4.8 mg 
of dibasic, anhydrous sodium phosphate (Sigma, St. Louis, MO), and 1.6 mg of 
polysorbate 20 (Sigma, St. Louis, MO) in 4ml of sterile water) to yield 25 
mg/ml and then diluted  with media into 0.1 mg/ml as an appropriate control.  
To yield 10 mM primary stock, 50 mg of gefitinib (Eurasian chemicals, India) 
was dissolved in 11.2 ml of DMSO (VWR, PA). The working concentration of 
gefitinib was 10 µM.  
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To yield 0.15 mg/ml (0.329 mM) of primary stock, 1 mg of W146 (Cayman 
chemical, MI) was dissolved in 6.67 ml of ethanol (VWR, PA). The stock 
solution was diluted with culture media to final concentration of 10 µM or 
1µM. 
Human MCP-1 neutralizing antibody, AF-279-NA and normal goat IgG (R&D 
Systems, MN) were reconstituted at 0.2 mg/ml in sterile PBS. 
 
3.9 Immunohistochemistry 
HUVEC and IMR-90 cells were fixed in microfluidic devices with 4 % 
paraformaldehyde (Sigma, St. Louis, MO) for 15 min at room temperature 
followed by PBS washing, twice. Cells were permeabilized by 0.1 % Triton X-
100 (Sigma, St. Louis, MO) for 10 min at room temperature and washed with 
PBS once, then blocked with 0.5 % BSA (Sigma, St. Louis, MO) blocking 
solution for 2 h at room temperature. VE-cadherin primary antibody (Enzo 
Life Sciences) was diluted to 1:100 and incubated with cells overnight at 4 °C . 
Microfluidic devices were washed with washing buffer (0.1% BSA in PBS) 3 
times, each with 5 minutes incubation time and then incubated with Alexa 
Fluor-conjugated goat anti rabbit-secondary antibody (Molecular Probes, 
Eugene, OR) at a dilution of 1:100 for 4 h at room temperature. Microfluidic 
devices were again washed with buffer 3 times, each with 5 min incubation 
time. Cells were then counterstained with 10 µg/ml Hoechst (Molecular 
Probes, Eugene, OR) and 100 times diluted 300 U Phalloidin rhodamine 
(Molecular Probes, Eugene, OR) for 30 min at room temperature. 
Fluorescence was detected using a confocal microscope (OLYMPUS, FluoView 
FV1000).  
 
3.10 Dextran concentration gradient assay 
HUVECs were seeded in the middle channel one day before the assays were 
run to form monolayer of HUVECs in the channel. Subsequently, 2 µM of 40 
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kDa (which resembled VEGF with molecular weight of 45kDa) Texas Red-
conjugated dextran (Molecular Probes, Eugene, OR) was infused into the 
right media channel while the middle/left channel was kept as EGM-2mv to 
allow formation of dextran concentration gradient across the collagen gel. 
Images were analyzed with Metamorph and Image J. 
 
3.11 Proteomic analysis 
In order to collect cultured media for proteomic analysis, 83 k cells HUVEC 
and 200 k cells IMR-90 were seeded in 6-well plates and subjected to the 
following conditions in culture media (EGM-2mv): 8 µM CPX and 250 nM S1P, 
8 µM CPX only, 250 nM S1P only and medium only. In a parallel experiment, 
endothelial CM (see above) was applied to IMR-90 in 6-well plates to study 
communication between endothelial cells and fibroblasts. The supernatant of 
each condition was collected and then centrifuged at 200 G for 5 min at room 
temperature to remove cells and kept at -20 °C in aliquots before proteomic 
analysis.  
Proteome profiler, human angiogenesis array kit (R&D Systems, MN) was 
used to detect the presence of angiogenesis-related proteins in the cell 
culture supernatant as per the manufacturer’s instruction. Briefly, 700 µl of 
cell culture supernatant were incubated with a primary biotinylated antibody 
mixture at room temperature for 1 h and then incubated with array 
membranes at 4°C overnight. Bound antibodies were detected and visualized 
with streptavidin-HRP chemiluminescent substrate using a chemiluminescent 
imaging system (Syngene, G:Box, UK), and the intensity was quantified 
through Image J software (http://rsbweb.nih.gov/ij/). 
ELISA assays (R&D Systems, MN) were run to quantitatively measure the 
protein concentration of VEGF, MCP-1 and PlGF as per the manufacturer’s 
protocol. Colorimetric enzyme reaction was performed as per manufacturer’s 
protocol and analysed in a microplate reader (Tecan, Sunrise Magellan, 
Switzerland) at 450 nm. The data obtained were processed using Prism 
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(GraphPad Software, CA) that is capable of generating a four parameter 
logistic (4-PL) curve fit.  
 
3.12 Western Blot 
Cell lysate was prepared from endothelial culture in 24-well culture plate 
where endothelia were subjected to 4 different pharmacological inductions 
as mentioned above. The protein concentration in each cell lysate was then 
determined by Bradford assay against the BSA standard curve. Subsequently, 
8 % resolving and 5 % stacking polyacrylamide gels were casted in house. 
Then, 10 µg of total protein from each sample was loaded and then the gels 
were run for electrophoresis together with ladder control and the proteins 
were then transferred to PVDF (Biorad, CA) membrane through 
electroblotting. Membranes were incubated with primary antibody against 
S1P1 (Cayman Chemical, MI) in a 1:200 dilution in 5% BSA-0.05% tween-PBS 
buffer overnight at 4 °C with gentle shaking. The membranes were washed 3 
times in 0.05% tween-PBS, 10 min incubation each. The membranes were 
then incubated with HRP-conjugated secondary antibody (Santa Cruz, TX) in 
1:2000 dilution for 1.5 h at room temperature followed by washing steps as 
mentioned. The membrane was exposed to x-ray film (Konica Minolta, Japan) 
for at least 10 s and developed using KD-90 developer and KF fixer (Konica 
Minolta, Japan). α-tubulin was used as a loading control and detected using 
primary antibody (Santa Cruz, CA) and HRP-conjugated secondary antibody 
(Santa Cruz, CA) both in 1:5000 dilution. The film was then scanned and 
analyzed using Image J (http://rsbweb.nih.gov/ij/) plugin, “Gels” that allows 




3.13 Quantification of sprouts in microfluidic 
devices 
The cell number is quantified by using the inbuilt Image J function, 3D objects 
counter, to measure the Hoechst stained nuclei across different depths from 
confocal images. The maximum sprout length of each gel region was 
determined by drawing a line from the edge of the collagen gel to the tip of 
the furthest grown sprout, using Image J software (http://rsbweb.nih.gov/ij/). 
In order to measure the skeletal length of the sprouts, 3D confocal 
fluorescence images of VE-cadherin staining were projected onto a 2D plane 
and processed in the following order: enhancing contrast, reducing noise 
through despeckling, smoothening through Gaussian blur, converting to 
binary image through auto threshold, and finally skeletonizing with the Image 
J plugin, AnalyzeSkeleton (see Figure 3-2) [129]. These manipulations were 
written into a macro that batch-processed the images automatically to avoid 
bias. Area of capillary sprouting was determined by accessing the VE-cadherin 
positive areas from the projected stacked image after automatic threshold. 
Estimated diameter was obtained by dividing area of capillary sprouting by 
skeletal length. Migration distance of migrating cells was measured by the 
shortest distance between nuclei position and the edge of collagen gel where 




Figure 3-2 Skeletal length measurement is made through skeletonizing confocal 
images.(a) Projected 2D image of VE-cadherin stained capillary network from 3D 
confocal stack images. The vertical yellow line represents the maximum sprout 
length, d that measures the distance of the furthest grown sprout from the edge of 
collagen gel. (b) Skeletonized image of (a) by using Image J plugin, AnalyzeSkeleton. 
Skeletal length is the total length of the skeletonized network. Scale bar = 100 µm.  
 
3.14 COMSOL Simulation 
The model was built based on a 2D transport of diluted species model by 
using COMSOL Multiphysics simulation software. The diffusion coefficients of 
40 kDa Texas red-conjugated dextran, VEGF and PlGF in cell culture media, 
collagen gel and alginate beads were estimated based on a 40 kDa inert 
molecule from Stokes-Einstein equation and also adapted based on previous 
findings [130-132]. The values of diffusion coefficient for VEGF and PlGF are 
identical based on Stokes-Einstein estimation because their molecular 
weights are both in the range of 40k Da [133, 134]. The secretion and 
consumption rates of VEGF and PlGF were calculated based on the ELISA 
results that I obtained previously and normalized against cell number in 
microfluidics. The initial concentration of 40 kDa dextran was set as 2x10-3 
mol/m3 in the right channel and 0 in every other region based on the 
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concentration of 40 kDa that has been added into the microfluidic. The initial 
concentration of VEGF and PlGF was set as 3.2x10-8 mol/m3 and 0 
respectively based on the concentration of these two proteins in culture 
media as determined through ELISA. The parameters are summarized in Table 
3 . 
 
Table 3 Parameters for COMSOL simulation 
 Dextran VEGF PlGF 




/s) 5.9 6.0 6.0 




/s) N.A. 5.5 5.5 




/s) 4.9 4.9 4.9 




) N.A. -3.04 2.84 









) 200000 3.20 0 
 
3.15 Statistical Analysis 
Numerical values were expressed as the means ± SE (standard errors) of at 
least three independent experiments. One way analysis of variance (ANOVA) 
with Newman-Keuls post-test was used to determine statistical significance 
when comparing multiple means. Student’s t-tests were conducted, when 
applicable, to compare means between two groups. Statements of 




 CHAPTER 4. MICROFLUIDIC 
DEVICES FOR ANGIOGENESIS 
RESEARCH 
 
Recent advances in microfluidic technologies have brought angiogenesis 
research to a new level and have provided insights on angiogenesis that 
conventional angiogenesis assays could not. The advantages of microfluidic 
platforms include the abilities to 
 observe the formation of capillary sprouting within a physiologically 
relevant 3D collagen gel matrix 
 form a endothelial monolayer that resembles that in a pre-existing 
blood vessels prior to angiogenesis 
 allow interactions of multiple cell types in a single device 
 establish control over solute concentration gradients 
These advantages are important in the study as the ability to form capillary 
sprouting with true lumen in a 3D matrix that can anastomose is the first step 
in pursuing solutions for therapeutic angiogenesis. This feature can be 
achieved by using microfluidics with loaded collagen gel as a scaffold. 
Moreover, the formation of endothelial monolayer prior to the capillary 
sprouting differentiates the angiogenesis process from vasculogenesis. As 
angiogenesis requires the interplay between endothelia and other cell types 
such as fibroblasts [22], the ability to culture multiple cell types in a single 
device makes microfluidic device an attractive platform to study angiogenesis. 
Angiogenesis is a highly regulated process that requires participation of 
numerous cytokines especially ones that can induce directed chemotaxis on 
endothelia [118, 126]. Therefore, microfluidics offer direct control over 
solute concentration gradients that can affect how the endothelia respond to 
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the cytokines, either added exogenously or secreted spontaneously from a 
nearby cell source. Microfluidic devices are powerful tools that can provide 
new insight to enrich the knowledge of current field but these advantages 
also come with certain price. The fabrication of microfluidic devices takes at 
least 3 days (discussed in details in Chapter 3: Materials and Methods) before 
they are ready for experiment. In addition, the sprouting experiment usually 
takes 4 days for more developed vascular network to be formed while the 
commercially available Matrigel and transwell assays usually do not last more 
than 24 h [135]. The long preparation process and experiment time frame for 
microfluidic assays restrict the potential to obtain large amount of data 
within limited time. The small operating volume is a double-edged sword in a 
microfluidic assay. The small operating volume saves reagents and the tiny 
microenvironment within a microfluidic device also offers greater control 
over solutes distribution [114]. However, general biochemistry assay such as 
ELISA will require higher amount of working volume than a typical 
microfluidic device can yield [136]. In addition, the retrievable number of cell 
from a single microfluidic device is usually too low for further quantifications 
such as western blot or PCR analysis. Therefore, culture media or cells have 
to be pooled from multiple devices for accurate analysis. Nevertheless, the 
advantages that microfluidic platform can offer outweigh its disadvantages 
for the studies on angiogenesis; therefore I have adopted it as a functional 
assay in my studies. Based on different designs of microfluidics, various 
treatments that are usually not applicable to conventional cell culture are 
made possible such as the application of shear and interstitial flows and 
mechanical stretching. Song et al. showed that sheared stress inhibited the 
VEGF-induced sprouting through nitric oxide signalling in a microfluidic 
angiogenesis assay [137]. In addition, they also showed that interstitial flow 
can increase the EC invasion into the collagen through a Rho-A dependent 
pathway and similar results were obtained by Vickerman et al. where they 
showed the interstitial flow not only improved cell migration but also 
vascular formation in another microfluidic assay [114, 137, 138]. The shear 
stress inhibition of angiogenesis ensures that the mature vessels with flow 
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can maintain a non-sprouting phenotype while vessels with low flow are 
prone to angiogenesis [137]. Meanwhile, the interstitial fluid pressure of solid 
tumours is usually higher than surrounding tissue which leads to the 
generation of interstitial flow that triggers the angiogenesis cascade [139]. 
Although those treatments are beyond the scope of this thesis they 
demonstrate the new dimension and perspective that microfluidic 
technology has brought to angiogenesis research. 
Design of the microfluidic device that I use consists of several main regions: a 
central channel where the endothelial cells were seeded flanked on each side 
by a chamber that contains a 3D matrix (collagen type 1 in this case), then 
two larger side channels with bead trap region for empty alginate beads or 
cell-containing alginate beads (see Figure 3-1). The trapezoidal posts at the 
two sides of gel region serve to contain the gel solution due to surface 
tension during filling, and stabilize the gel against mechanical disruption. The 
collagen gel regions contained between the trapezoidal posts serve as 
observing regions for the growth of vascular network (Figure 3-1). The 
alginate beads with the size of around 100 µm can be injected into the bead 
trap region through a bead inlet and they are contained by rows of square 
posts spaced 70 µm apart (Figure 3-1). 
With those features mentioned, endothelial cells in the middle channel form 
a monolayer 2 days post seeding which serves as a pre-existing blood vessel 
that is adjacent to 3D collagen matrix for studying angiogenesis (Figure 4-1). 
Based on Figure 4-1, I have observed that endothelial cells formed a 
continuous monolayer in the microfluidic channel that covered the flank side 
of collagen gel and also the glass bottom and PDMS top surfaces. Although 
the cross-section of the channel is rectangular, the continuous EC monolayer 
preferred a cylindrical tubular structure and Zheng et al. showed a similar EC 
curvature in a PDMS microfluidic channel [125]. Barreto-Ortiz et al. also 
showed that the circumferential alignment of EC deposited-collagen IV, 
fibronectin and laminin; that are important in helping vessel to withstand the 
circumferential stress, can only be maintained on a curved surface but not on 
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2D flat surface [140]. The growth of new sprouts took place from this curved 
EC monolayer and extended into the collagen regions. Blood vessels are 
usually surrounded by layers of extracellular matrix including collagen type I, 
IV, XVIII, laminin and proteoglycans [141]. Therefore, I cannot rule out that 
the possibility that PDMS top and glass bottom would affect the angiogenic 
behaviour in the system even though the region of interest is the collagen 
scaffold with growing sprouts. Nevertheless, Mammoto et al demonstrated 
that EC grown on stiffer fibronectin-coated polyacrylamide gel (4000 Pa) 
showed higher expression of VEGFR2 but the receptor expression levels were 
significantly lower in EC grown on rigid glass coated with fibronectin [142]. In 
addition, Lopez-Garcia also showed that the stiffness of 2.5 mg/ml (the 
concentration that I used) of collagen type I at physiologically relevant 
displacement rate was near the range of 4000 Pa [143]. Therefore, the EC 
that adhered to the flank side of collagen might be more responsive to VEGF 
induction due to higher expression of VEGFR2.  
As fibroblasts are usually more abundant than endothelial cells in vivo i.e. 27 % 
of cells in the heart are comprised of fibroblasts but only 7 % are endothelial 
cells, I have to accommodate about 4 times more fibroblasts than endothelia 
in the devices to address this difference [144]. In addition, as the cell size of 
fibroblasts is generally larger than endothelial cells, the common equal-
channel width design shown in Figure 4-2 that I previously used could not 
accommodate a sufficient number of fibroblasts to support the growth of 
new vessels. In fact, the ratio of endothelia to fibroblasts in the equal-
channel width design is 3:1. Fibroblasts favour collagen gel and they invade 
into collagen matrix readily which would obstruct the observation of sprout 
formation in the 3D collagen gel and might even cause gel contraction in 
some cases. In order to address both cell number and fibroblast invasion 
issues, cell encapsulation by using alginate beads was chosen, thus the need 
for including bead trap regions in the enlarged side channels in the 
microfluidic devices.  
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Alginate bead encapsulation can prevent most of the fibroblasts from 
entering the collagen gel matrix and only some of the encapsulated 
fibroblasts would break free from alginate beads and invade into collagen gel 
in the later part of experiment  .The number of fibroblasts in the beads can 
be controlled by adjusting the concentration of fibroblast in suspension 
during encapsulation [9]. As the diameter of alginate beads fall in the range 
of 70 to 100 µm, they are trapped within bead trap region by the square 
posts during injection. Consequently, fibroblasts in the side channel only 




Figure 4-1 Schematic diagram of microfluidic devices and experimental setup. (a) 
Endothelial cells were seeded in the middle channel and cultured for one day to 
form a monolayer that represented a pre-existing vessel for studying angiogenesis. 
Red spheres denote fibroblast-encapsulated alginate beads while green spheres 
denote empty alginate beads. Alginate beads were introduced via the bead inlet and 
contained in the bead trap regions of side channels by square posts with 70 µm 
spaces. (b) Confocal image of endothelial cells with Hoechst stained nuclei (blue), 
rhodamine phalloidin stained actin (red) and Alexa fluor 488 immunostained VE-
cadherin (green), formed a monolayer lining the medium channel. The monolayer is 





Figure 4-2 Schematic diagram of microfluidic device with equal channel width. This 
microfluidic device consists of two media channels with 500 µm width which are 
separated by a matrix region and are reconnected downstream at the outlet port. 
The trapezoidal pillars at the matrix region provide sufficient surface tension to 
contain the collagen gel during gel filling. 
 
As paracrine signalling is expected to affect the endothelial sprouting 
behaviour, I then validated the system by running dextran diffusion assay to 
determine the diffusion and concentration gradient profiles in the 
microfluidic devices. Texas Red-conjugated dextran (Txr-Dex) with a 
molecular weight of 40 kDa was diluted in media to yield 2 µM solution. The 
solution was injected into the right channel where fibroblasts were seeded to 
simulate the diffusion profile of fibroblasts secreted VEGF (45 kDa) across the 
collagen gel region. From Figure 4-3, I determine that Txr-Dex diffused 
through the collagen gel attaining a steady concentration gradient profile at 
24 h. I also observed that Txr-Dex reached a plateau near the right edge of 
collagen where endothelial cells formed a monolayer. This is due to the 
diffusive barrier that is created by endothelial monolayer and this also shows 
that the integrity of endothelial monolayer was not compromised in the 
experiments. With these results, I confirmed that proteins secreted from 
fibroblasts could form steady concentration gradients across the collagen gel 




Figure 4-3 Concentration gradient assays in microfluidic device. (a) Schematic 
drawing of microfluidic device and the arrow head denotes the direction of diffusion. 
(b) 4x epifluorescent image of microfluidic device with 2 µM of TxR-Dex injected into 
right channel at 24 h time point. The middle channel was seeded with HUVECs that 
formed a monolayer whereas the right channel was filled with alginate-encapsulated 
fibroblasts. The yellow rectangular box denotes the region taken for quantitative 
measurement of fluorescent intensity across the gel region. (c) Quantitative plots of 
fluorescent intensity versus distance across the gel region. Distance 0 denotes the 
edge between the middle channel and the collagen gel. The plots show that the 
concentration gradients reached a plateau near the right edge of collagen gel at 24 h. 
Scale bar = 100 µm. 
 
In order to further validate this device for studying angiogenesis, I employed 
VEGF, a well-known potent angiogenic factor to induce angiogenesis in the 
microfluidics. Therefore, 20 ng/ml of VEGF was added to the right and left 
channels that contained fibroblasts encapsulated alginate beads (right 
channel) and empty alginate beads (left channel) respectively but not in 
middle channel to create VEGF concentration gradients in both collagen gels. 
From the phase contrast images of Figure 4-4, I can see that VEGF could 
induce capillary sprouting after 4 days of culture. Based on the images, I 
could confirm that the sprouts formed in the collagen contained lumina and 
that they also formed in 3D. The sprouts that grew in 3D could anastomose in 
a later stage once they extended further into the collagen gel region which is 
yet another key feature in a functional vessel network. Hence, I successfully 
demonstrate that microfluidic devices as exceptional functional platforms for 
studying angiogenesis in a 3D context with applied chemokine gradient in a 




Figure 4-4 VEGF-induced capillary sprouting in 3D collagen gel. (a) 4x Phase contrast 
image of VEGF-induced capillary sprouting in 3D collagen gel. (b) Magnified image of 
specified area in (a) that shows the sprouts with lumen grew in collagen gel across 
different depth and also shows the anastomosis of two nearby sprouts. Scale bar = 
100 µm.  
 
As fibroblasts have been shown to stabilize the formation PHi induced 
capillary-like structure [4], I then carried out systematic quantifications to 
confirm the stabilizing effects of fibroblasts on immature sprouts. Fibroblasts 
are able to induce and maintain capillary sprouting even in the absence of 
any exogenous angiogenic stimulus as they could secrete various angiogenic 
chemokines including VEGF naturally [145]. In microfluidic assay, some 
immature sprouts could form during the early stage of the experiments. 
However, those immature sprouts could not be maintained and would either 
regress or detach from the endothelial monolayer if they were growing 
towards empty alginate beads on day 4. Conversely, the capillary sprouts that 
grew towards fibroblasts were stabilized as reflected by the skeletal length, 
cell number and maximum length of the sprouts. The skeletal length and 
maximum length of sprouts growing towards fibroblasts encapsulated beads 
were about 2x more than the sprouts growing towards empty beads while 
the cell number in the sprouts was about 3x more. These results confirm the 
importance of fibroblasts in inducing and stabilizing capillary sprouting in 
microfluidics and the experimental results that I show in following chapters 
are always with fibroblasts encapsulated alginate beads in right channel while 
empty alginate beads in left channel serve as control unless otherwise 






Figure 4-5  Fibroblasts induce and stabilize endothelial sprouting in collagen gel. (a) 
4x phase contrast image of endothelial cell sprouting assay in cell culture media on 
day 4. (b) and (c) 20x phase contrast images of detached sprouts and endothelial 
cells from the EC monolayer that were growing towards empty alginate beads. (d) 
and (e) 20X phase contrast images of sprouts growing towards alginate-
encapsulated fibroblasts . (f) Quantification of skeletal length, cell number and 
maximum sprout length for sprouts growing towards empty beads and towards 
fibroblast-encapsulated beads in cell culture media.  Without the support of 
fibroblasts, sprouts would regress or detach from EC monolayer on day 4. Scale = 
100 µm. * p < 0.05 
 
Barkefors et al. have shown that VEGF and FGF gradients are important in 
inducing the endothelial migration in a microfluidic platform while Gerhardt 
et al. also demonstrated that VEGF distribution is important in guiding tip cell 
migration and disruption of the VEGF gradients would lead to misguidance of 
tip cell filopodia in a mice retinal angiogenesis model [126, 146]. The dextran 
assay proved that concentration gradients can be maintained across the 
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collagen gel, which is an absolute advantage of using microfluidics in studying 
angiogenesis in vitro. Formation of functional vascular networks involves 
multiple processes including cell proliferation, guided migration, formation of 
lumen, branching of neo-vessel, anastomosis of vessels and vessel pruning 
[147]. With a single microfluidic assay, I could observe all the above-
mentioned processes and the morphologies of vascular networks in great 
detail.   
The importance of mural cells in vascular development has been highlighted 
in the literature over the years and among those assisting cell types, I am 
particularly interested in employing fibroblasts as mediating cells in 
thesystems as it has been shown that fibroblasts could regulate angiogenesis 
through growth factor secretion such as VEGF, ANG-1 and HGF and also 
through matrix remodelling by secreting MMPs or depositing collagen and 
fibronectin [21, 22]. Most importantly, our group has previously shown that 
fibroblasts could response more aggressively to the stimulation of PHi and 
leads to HIF-1a stabilization which then promotes angiogenesis [4]. I have 
demonstrated the ability of incorporating fibroblasts encapsulated alginate 
beads in the devices that can promote angiogenesis even in the absence of 
exogenously added angiogenic proteins.  
Various in vitro angiogenesis models that can study different stages of the 
angiogenesis processes such as matrix degradation, migration, proliferation 
and morphogenesis were summarized by Goodwin [148]. Among various 
models that are available, only limited in vitro models are able to capture the 
whole event of angiogenesis and this microfluidic assay is one of the few. The 
commonly used Matrigel assay or Transwell assays only provide information 
on endothelial cell morphogenesis and migration respectively [148]. 
Endothelial cells can form capillary-like structures (CLS) spontaneously when 
they are cultured on Matrigel. Often time, the CLS on Matrigel grow in 2D but 
tubular structures may be observed too [149]. Nonetheless, the matrix 
degradation and branching events that can be observed in a microfluidic 
assay are not able to be shown in a Matrigel assay. In addition, the 
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application of concentration gradient of angiogenic stimuli in a Matrigel assay 
is usually very difficult. Commercially available Transwell assay can be used to 
study the endothelial migration towards a higher concentration of 
chemoattractant but endothelial cells will not form capillary or tubular 
structure in this assay [148].  Other more developed assay such as microbead 
assay allows the observations of sprouting events from endothelial cell 
coated microbeads that are embedded in a matrix [150]. This assay can 
essentially capture all stages of angiogenesis but the quantification might be 
challenging as the vessels grow in radial direction.  
In short, the microfluidic device that I use have been validated through the 
studies of its diffusion profile, its ability to allow formation of sprouts with 
lumina and also its versatility in accommodating a second cell type together 
with endothelia. With these features, the microfluidic device serves as an 
excellent platform for studying angiogenesis in vitro.  
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 CHAPTER 5. RESULTS 
 
5.1 Comparisons between PHis 
Among the three PHis tested, CPX showed the greatest angiogenic potential 
while PDCA could induce little to no sprout formation. When these three PHis 
were introduced individually into microfluidics, 8 µM CPX could help promote 
angiogenesis in collagen on the right side that was adjacent to fibroblast-
encapsulated beads within 4 days while 10 mM PDCA induced the least 
sprout formation and 100 µM HDZ showed angiogenic potential that was 
greater than PDCA but obviously weaker than CPX (Figure 5-1 (a)-(c)).  
Similarly, S1P that can affect angiogenesis through multiple pathways (as 
mentioned in Introduction) also holds great promise for therapeutic 
angiogenesis [89]. While the angiogenic effects of PHIs and S1P have been 
shown individually, it has remained unclear if they would further promote 
angiogenesis as a combination. I then tested if the angiogenic potentials of 
PHis could be further boosted by combining them with S1P. Interestingly, I 
did not observe any increase of capillary sprouting in the preliminary 
experiments when PDCA was coupled with S1P but I could clearly observe 
that both HDZ and CPX responded well with the addition of S1P and showed 
increased sprout formation (see, e.g., Figure 5-1 (d)-(e)). In addition, the 
sprouts induced by CPX + S1P extended more than 800 µm into collagen gel 
within 4 days as compared to 400 µm with the HDZ + S1P combination and 
less than 150 µm with PDCA + S1P. CPX + S1P induced capillary sprouting also 
showed complex vascular structure indicating sprout anastomosis, hence this 
combination held the promise to be used to develop fully functional 
networks. Since CPX showed the greatest angiogenic potential among the 
PHis tested, I focused on CPX and its combination with S1P in inducing 




Figure 5-1 Different PHis show differential angiogenic potentials. (a) – (c) Phase 
contrast images of 10 mM PDCA, 100 µM HDZ and 8 µM CPX induced angiogenesis 
in collagen that is adjacent to the fibroblasts encapsulated alginate beads in right 
channel. (d) – (e) Phase contrast images of endothelial sprouting under the 
induction of different PHis combined with S1P. CPX outperformed HDZ and PDCA in 
inducing angiogenesis in in vitro microfluidic assay, regardless of being applied 
individually or in combination with S1P. Red bars denote approximate length of 
sprouts. Scale bar = 100 µm. 
 
5.2 In combination, CPX and S1P induce an 
extensive vascular network with true lumina 
I then proceeded to study the pro-angiogenic effects of CPX and S1P in 
microfluidics in the presence of fibroblasts as mediating cells. In order to 
increase fibroblast density while preventing direct contact with endothelial 
cells, fibroblasts were encapsulated in microbeads as described previously. I 
tested four conditions in microfluidic devices containing encapsulated 
fibroblasts: EGM-2mv as control, 8 µM CPX in EGM-2mv, 250 nM S1P in EGM-
2mv and 8 µM CPX + 250 nM S1P in EGM-2mv. The concentrations of CPX 
and S1P were adapted from previous reported assays that could effectively 
induce angiogenesis in vitro [4, 151].  
Endothelial cells showed some spontaneous sprouting into collagen gel 
before the application of the mentioned conditions but those sprouts 
persisted only if growing towards fibroblasts and these results were 
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consistent with previously shown data that indicated stabilization by 
fibroblasts of endothelial sprouting (Figure 4-5). With fibroblasts only, I 
observed relatively fewer longer sprouts, which did not anastomose. When 
CPX or S1P were introduced an increase of sprout length ensued with the 
formation of a basal network and formation of anastomoses. However, when 
CPX and S1P were combined, the resulting sprouts almost traversed the 
entire collagen gel width and extended as long as 0.8 mm in 4 days (Figure 
5-2 (a)-(d) and Figure 5-3). This was comparable to the previous reported 
growth speed of capillaries in a rabbit corneal model of 0.2 mm/day [152].  
I assessed skeletal length, maximum sprout length and the number of cells 
forming sprouts to compare the effectiveness of CPX and S1P in inducing 
angiogenesis. Skeletal length was calculated as the sum total of all sprout 
lengths, and used to document sprout density and complexity. CPX + S1P 
induced dense sprouting networks with 20800 ± 2790 µm skeletal length 
while S1P, CPX and media control produced 12900 ± 2220 µm, 9450 ± 195 µm 
and 6310 ± 1550 µm, respectively. Maximum length was determined from 
the longest sprouts to assess sprouting distance covered. The CPX + S1P 
combination again induced capillary sprouting that extended furthest into 
the collagen gel, 525 ± 69 µm as compared to S1P, CPX and media control 
that had maximum lengths of 372 ± 58.1, 297 ± 46.6 and 232 ± 52.6, 
respectively. The cell number of sprouts was an indicator of maturity in terms 
of endothelial participation in building sprouts where CPX + S1P increased the 
number of cells in sprouts to 678 ± 80.9 cells as compared to S1P, CPX and 
media control which had only 398 ± 67.0, 301 ± 76.7 and 241 ± 47.8 cells in 
the sprouts, respectively. All three metrics demonstrated that the CPX + S1P 
outperformed the monosubstance treatment with statistical significance 
(Figure 5-2 (e)-(g)). Confocal imaging demonstrated that the sprouts formed 
in the presence of CPX/S1P developed into a complex vascular network 
structure with clear evidence for lumina which can be clearly seen in the 
confocal images of the vascular network (Figure 5-4). The diameter of the 
capillary sprouting ranged between 10 and 30 µm where sprouts near the 
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endothelial monolayer were typically wider and comprised more cells 
because they were more mature as compared to the sprout tips that 
extended deeper into the collagen gel. VE-cadherin staining of the vascular 
network also confirmed that the integrity of the intercellular junctions was 
maintained during angiogenesis.  
 
 
Figure 5-2 CPX and S1P together induce an extended vascular network in the 
presence of fibroblasts. (a) – (d) 4x phase contrast images of endothelial cells 
sprouting into collagen gels under different pharmacological conditions. Sprouts on 
the right side of the channel grow toward encapsulated IMR-90 fibroblasts. Red bars 
denote approximate length of sprouts. (e) – (g) Quantifications of skeletal length, 
cell number and maximum sprout length. CPX and S1P induce a more complex 
vascular network structure that is longer and contains more cells. Scale bar = 100 





Figure 5-3 Sprouts that  extend three quarters of the way across the collagen region 
under the induction of CPX + S1P . Stitched 20 X confocal images with Hoechst 
stained nuclei (blue), rhodamine phalloidin stained actin (red) and Alexa fluor 488 
immunostained VE-cadherin (green) show that sprouts grew and extended around 




Figure 5-4 In combination, CPX and S1P induces formation of vascular network 
structure with defined lumina. (a) Stitched; (b) and (c) sectioned 20x confocal images 
of Hoechst stained nuclei (blue), rhodamine phalloidin stained actin (red) and Alexa 
fluor 488 immunostained VE-cadherin (green) show sprouts that anastomose under 
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8 µM CPX and 250 nM S1P induction. White arrows indicate lumina of endothelial 
sprouts with diameters around 20 µm. Scale bar = 100 µm 
 
5.3 CPX induces secretion of complementary 
angiogenic proteins from both fibroblasts and 
endothelial cells 
As endothelia and fibroblasts were separated by a collagen gel matrix in two 
adjacent channels, I hypothesized that soluble factors that can diffuse 
through collagen gel were responsible for the CPX + S1P induced 
angiogenesis. Therefore, I assessed the secretion of angiogenic factors by 
fibroblasts and endothelial cells in the presence of CPX and S1P, respectively. 
Proteome profiler data showed increased secretion of 4 proteins including 
PlGF (4.9 fold), IL-8 (3.7 fold), EGF (4.7 fold) and endothelin-1 (1.8 fold) by 
CPX + S1P treated endothelial cells among 55 angiogenesis related proteins 
that the proteome profiler can detect (Figure 5-5 (a)-(d)). Highly comparable 
increases were found in the presence of CPX alone with the exception of EGF 
secretion where CPX + S1P combination further boosted its secretion level by 
another 45 % as compared to CPX alone. No significant increase in proteomic 
secretions was observed with S1P only. The secretions of these factors were 
tested in fibroblast culture but fibroblasts did not express PlGF, EGF and 
endothelin-1 and the expression level of IL-8 was not altered by the 
treatment of CPX + S1P. 
In fibroblasts, CPX + S1P increased the expression of HGF (1.6 fold), IGFBP-2 
(2.2 fold), uPA (1.9 fold) and VEGF (11 fold) (see Figure 5-5 (f)-(i)). Similar to 
proteomic secretion by EC, highly comparable increases were found in the 
presence of CPX alone, and none were observed with S1P only. Based on 
proteomic profiling results, other angiogenesis related proteins including 
amphiregulin, IGFBP-3 and pigment epithelium-derived factor (PEDF) were 
detected in fibroblast cultures while endostatin/collagen XVIII, pentraxin 3 
(PTX3), plasminogen activator inhibitor (PAI)-1, tissue inhibitor of 
54 
 
metalloproteinases (TIMP)-1 and thrombospondin-1 were detected in both 
cultures but their expression levels were not affected by neither CPX nor CPX 
+ S1P combination.  
I validated these data for PlGF and VEGF through ELISA. I found that CPX + 
S1P can increase the PlGF secretion rate in endothelia from 765 ± 37.1 (± SE) 
to 3300 ± 631 pg/ml-Million cell-day while S1P did not show any significant 
effect; these results were similar to those I have obtained through proteomic 
profiling. In fibroblasts I confirmed an increase of VEGF secretion from 280 ± 
59.6 to 2080 ± 60.3 pg/ml-Million cell-day when fibroblasts were subjected to 
induction by CPX + S1P as compared to basal control. Again, while CPX alone 
induced comparable increase of VEGF production, S1P alone did not elicit 




      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
 
Figure 5-5 CPX induces secretion of different angiogenic proteins by endothelial cells 
and fibroblasts. (a-d): proteomic analysis plots of proteins upregulated in HUVEC 
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treated with CPX + S1P. The upregulated proteins are PlGF (4.9x), IL-8 (3.7x), EGF 
(4.7x) and endothelin-1 (1.8x). CPX and S1P combination further increased EGF 
expression by 45 % as compared to CPX only. (f-i): proteomic analysis plots of 
proteins upregulated in IMR-90 fibroblasts treated with CPX + S1P. The upregulated 
proteins include HGF (1.6x), IGFBP-2 (2.2x), uPA (1.9x) and VEGF (11x). CPX appears 
to be the main compound causing the observed upregulation. (e) and (j): 
representative images of 3 proteomic profiler membranes showing differences in 
protein secretion between CPX and S1P treated group and non-treated group 
(culture media control). (k) and (l): ELISA quantitation of PlGF and VEGF 
corroborating semi-quantitative results shown in (a) and (i) where PlGF secretion 
was increased from 765 ± 37.1 (± SE) to 3300 ± 631 pg/ml-Million cell-day while 
VEGF was upregulated from 280 ± 59.6 to 2080 ± 60.3 pg/ml-Million cell-day. 
Fibroblasts were cultured in VEGF free media for ELISA quantification to obtain true 
secretion rate of VEGF by fibroblasts. Error bars denote SE. * p ≤ 0.05, ** p ≤ 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001 
 
Table 4 Angiogenic proteins secreted by EC and fibroblasts under the effects of CPX 
+ S1P 
Proteins Fibroblasts HUVEC Changed by 
HGF + ++ - CPX 
IGFBP-2 + ++ - CPX 
uPA + ++ - CPX 
VEGF + ++ - CPX 
Endothelin-1 - + ++ CPX 
PlGF - + ++ CPX 
EGF - + ++ CPX 
IL-8 + + + ++ CPX 
MCP-1 
+ + ++ + CPX/S1P 
+ ++ N/A Endothelial CM 
“+++” denotes upregulation of protein secretion; “-“ denotes no protein secretion  





5.4 Effects of VEGF on CPX + S1P induced 
Angiogenesis 
Among the proteins that were detected in fibroblast culture, VEGF was one 
of the most potent pro-angiogenic chemokines. I have confirmed that CPX 
and its combination with S1P could induce upregulation of VEGF in fibroblasts 
through proteomic profiling membrane and ELISA. Besides, the dextran assay 
shown earlier also confirmed that solutes in the side channel could diffuse 
through the collagen gel and reach EC in the middle channel. Therefore, I 
hypothesized that VEGF secreted by fibroblasts played a significant role in 
CPX + S1P induced angiogenesis in the in vitro microfluidic assay. In order to 
test the angiogenic potential of VEGF in these settings, Avastin (also known 
as bevacizumab) that could bind to and inhibit VEGF was employed. Avastin 
was used at a concentration of 0.1 mg/ml based on previous in vitro testing in 
tube formation assays and also its recommended dosage for clinical cancer 
treatment [153]. As shown in Figure 5-6 (a)-(d), 0.1 mg/ml of Avastin could 
reduce the CPX + S1P induced capillary sprouting back to background levels in 
the right collagen gel which was comparable to EGM-2mv cell culture media 
control. Meanwhile, 0.1 mg/ml of human IgG did not show inhibitory effects 
on CPX + S1P induced angiogenesis. Although endothelia that invaded into 
left collagen gel (towards empty alginate beads) could not be maintained and 
many had detached from monolayer and turned into migrating cells, I could 
observe that Avastin also greatly hindered cell migration as compared to IgG 
control or CPX + S1P positive control. I then quantified the results by 
measuring the skeletal length, cell number and maximum sprout length of 
the sprouts. The inhibitory effects of Avastin were clearly seen in all three 
metrics that I tested where skeletal length was reduced from 12300 ± 2170 to 
4210 ± 402 µm, cell number was decreased from 303 ± 96.0 to 108 ± 28.5 and 
maximum sprout length was also shortened from 394 ± 51.6 to 144 ± 33.3 
µm as compared to IgG control. With the confirmation from these 
quantification results, the importance of VEGF in CPX + S1P induced 




Figure 5-6 Avastin inhibits CPX + S1P induced angiogenesis. (a) – (d) 4x phase 
contrast images of CPX+ S1P induced capillary sprouting in collagen gel in the 
presence of fibroblasts encapsulated alginate beads. With 0.1 mg/ml of Avastin, CPX 
+ S1P induced angiogenesis was reduced to basal level similar to culture media 
control. Red bars denote approximate length of sprouts. (e) – (g) Quantifications of 
skeletal length, cell number and maximum sprout length. Avastin reduced capillary 
sprouting density in microfluidics that led to shorter skeletal and maximum sprout 
length and fewer cells. Scale bar = 100 µm. Error bars denote standard error. * p < 
0.05 
 
I also observed that Avastin not only reduced the density of capillary 
sprouting but also changed the morphologies of the sprouts formed. As 
illustrated in Figure 5-7, Avastin resulted in sprouts with larger diameters as 
59 
 
compared to the other three conditions. The diameter of sprouts increased 
from 16.4 ± 0.9 to 21.8 ± 1.6 µm or 33 % increment as compared to IgG 
control. The confocal images also confirmed that lumen formation in capillary 
sprouts was independent of the presence of Avastin but I observed a clear 
increase in lumina diameter when Avastin was introduced.  
 
Figure 5-7 Avastin increases diameter of sprouts. (a) 4x phase contrast images of CPX 
+ S1P induced capillary sprouting in microfluidics with 0.1 mg/ml Avastin or (c) 0.1 
mg/ml IgG. (b) and (d) Magnified images of specified areas (marked by red and 
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green rectangles) in (a) and (c), respectively that show  detailed morphologies of 
sprouts in collagen gel. (e) and (f) sectioned 20x confocal images of Hoechst stained 
nuclei (blue), rhodamine phalloidin stained actin (red) and Alexa fluor 488 
immunostained VE-cadherin (green) show that sprouts formed lumina under 8 µM 
CPX and 250 nM S1P induction with (e) Avastin or (f) IgG control. White arrows 
indicate lumina of endothelial sprouts. (g) Quantifications of diameter of sprouts 
under the effects of culture media, CPX + S1P, CPX + S1P + Avastin and CPX + S1P + 
IgG. The diameter of sprouts was increased by 33 % in the presence of Avastin as 
compared to IgG control but the diameters of sprouts between non-Avastin treated 
groups were not significantly different. Scale bar = 100 µm. Error bars denote 
standard error. * p < 0.05 
 
5.5 Effects of EGF on CPX + S1P induced 
Angiogenesis 
As demonstrated earlier, VEGF that played an important role in CPX + S1P 
induced angiogenesis was prominently upregulated by CPX in fibroblast 
culture. I also showed that CPX could upregulate multiple proangiogenic 
proteins in endothelial culture including PlGF, IL-8, EGF and ET-1. Since EGF 
secretion was further increased by CPX + S1P by another 45 % as compared 
to CPX alone, I hypothesized that EGF was also important in CPX + S1P 
induced angiogenesis in microfluidics. In order to test this hypothesis, I 
utilized a tyrosine kinase inhibitor, Gefitinib, which targeted the tyrosine 
kinase domain of EGF receptor to try inhibiting CPX + S1P induced 
angiogenesis in in vitro microfluidics. Gefitinib was used at 10 µM based on 
the previously reported in vitro inhibition dose [154]. Surprisingly, I observed 
no negative effects on capillary sprouting when I introduced Gefitinib 
together with CPX + S1P as shown in Figure 5-8. The migration of endothelia 
and the sprouting density in collagen gel were similar between the Gefitinib 
treated group, vehicle control group and CPX + S1P positive control group. 
Therefore, I confirmed that Gefitinib was not effective in against CPX + S1P 
induced angiogenesis in the in vitro settings which also suggested that EGF 




Figure 5-8 EGF receptor inhibitor, Gefitinib does not affect CPX + S1P induced 
angiogenesis. (a) – (d) 4x phase contrast images of endothelial capillary sprouting in 
collagen gel in the presence of fibroblasts encapsulated alginate beads under 
different pharmacological conditions. Gefitinib did not negatively regulate CPX + S1P 
induced capillary sprouting in collagen gel as compared to vehicle treated group. 
Red bars denote approximate length of sprouts. Scale bar = 100 µm. Error bars 
denote standard error. * p < 0.05 
 
5.6 S1P increases cell migration in microfluidics 
Through proteomic profiling assay and ELISA, I have shown that CPX was 
responsible for the upregulation of multiple angiogenic proteins from both 
endothelial and fibroblast cultures. Furthermore, the VEGF ligand inhibition 
experiment also suggested that CPX induced VEGF was important in CPX + 
S1P promoted angiogenesis. However, the role of S1P remains unclear 
especially since no significant reduction of angiogenic events was observed 
when an EGFR inhibitor was employed even though S1P in combination with 
CPX further boosted EGF secretion by 45 % in endothelial culture. I then 
continued the studies to look into direct pro-angiogenic effects of S1P on 
endothelia instead of possible paracrine or autocrine effects induced by S1P. 
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Microfluidic serves as an excellent platform for studying 3D cell migration in 
particular the design that I employed as it presents a collagen gel control on 
one (control) side (towards empty alginate beads) where endothelia received 
no inducement to form capillary sprouts due to the absence of fibroblasts. 
Instead, most of the endothelia that invaded into collagen gel on the control 
side would initially form immature sprouts but then detached from the 
endothelial monolayer and converted to individual cell migration on day 4. 
Based on previous experiments, I observed that whenever S1P was 
introduced, large numbers of endothelial cells showed migrating behavior in 
collagen gel on the control side as compared to the treatment groups 
without S1P (see Figure 5-9 (a-d)). I then quantified the number of migrating 
cells and migration distance on the control side to confirm if S1P increased 
endothelial cell migration. The quantification results were in line with 
qualitative comparison where S1P and CPX + S1P increased the number of 
migrating cells from 12.3 ± 1.7 in the media control group to 48.5 ± 6.4 and 
68.8 ± 11.1, respectively. In the same context, the endothelial migration 
distance measured from the S1P and CPX + S1P treated groups were 
increased from 135 ± 21 µm in the media control group to 319 ± 14 and 327 ± 
11 µm, respectively. In contrast, CPX did not influence endothelial cell 
migration as determined by both metrics used. Consequently, the pro-
migratory effects of S1P have been confirmed in the in vitro microfluidic 




Figure 5-9 S1P promotes endothelial cell migration. (a) – (d) 4x phase contrast 
images of endothelial cells sprouting and migrating into collagen gels under different 
pharmacological conditions. Endothelia migrated into collagen gel on the control 
side (towards empty alginate beads) of the channel. Red bars denote approximate 
length of migration distance. (e) – (f) Quantifications of cell number and migration 
distance. S1P promoted endothelia invasion into collagen gel and also increased 
endothelial migration distance but these effects were not seen in CPX treated 
groups. Scale bar = 100 µm. Error bars denote standard error. * p ≤ 0.05, ** p ≤ 0.01, 




5.7 Expression of S1P1 on Endothelia 
Several reports have indicated that S1P could induce endothelial cell 
migration through S1P1 activation in in vitro transwell assays [97, 155]. It has 
also been shown that S1P1 expression is dependent on type of endothelial 
cell [156]. Therefore, I proceeded to determine if S1P1 was expressed on the 
HUVEC that I used. If it was, I then asked if its expression could be altered by 
either CPX or S1P. Based on Figure 5-10, I confirmed that S1P1 is indeed 
present on the endothelia I used and surprisingly, its expression levels were 
also increased when treated with either CPX alone, S1P alone or CPX + S1P 
combination as compared to the media control group.   
 
Figure 5-10 Expression of S1P1 on endothelia is affected by S1P and CPX. (a) 
Immunoblots were stained with antibodies against S1P1 and α-tubulin to detect S1P1 
expression in endothelial cell lysate under different pharmacological conditions. α-
tubulin was used as loading control. (b) Quantification of fold change of treatment 
groups as compared to EGM media control group. Error bars denote SE. 
 
5.8 Angiogenic effects of S1P were mediated 
through S1P1 receptor 
S1P exerts its functions on cells through five G-protein coupled receptors, 
S1P1 to S1P5 [89]. As previously reported, S1P1 is involved in angiogenesis and 
I have also shown that endothelia expressed higher S1P1 level with CPX or 
S1P treatment [101]. In order to further investigate its importance in CPX + 
S1P induced angiogenesis, a S1P1 receptor specific inhibitor, W146 was used 
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to determine if S1P could enhance angiogenesis through S1P1 in the 
microfluidic settings. W146 was used at 10 µM based on previously reported 
concentration that could fully inhibit ligand induced internalization of S1P1 
and its downstream events in vitro [157]. Treatment with 10 µM of W146 in 
all channels effectively reduced the sprouting response induced by CPX + S1P 
to baseline levels. Although I observed the negative effects on angiogenesis 
caused by equal volume of vehicle (ethanol), the inhibitory effects caused by 
W146 could still be clearly differentiated from the vehicle control group 
(Figure 5-11 (a)-(d)). I then quantified the skeletal length, number of cells and 
maximum length of sprouts to further confirm the inhibitory effects of W146. 
As demonstrated in Figure 5-11 (e)-(F), the skeletal length of sprouts in the 
W146 treated group was reduced from 9670 ± 2150 to 2910 ± 899 µm; while 
number of cells was reduced from 239 ± 38 to 93 ± 19 and maximum sprout 
length was also reduced from 325 ± 33 to 119 ± 33 µm as compared to the 
vehicle control. Similar to qualitative comparisons based on phase contrast 
images, the vehicle control showed slight inhibitory effects as compared to 
the CPX + S1P positive control group but this did not affect the observation of 
true inhibition caused by W146. These results not only confirm the 
importance of S1P1 in CPX + S1P induced angiogenesis but also demonstrate 
the usefulness of microfluidics in differentiating various degrees of inhibition 





Figure 5-11 S1P1 specific inhibitor, W146 inhibits CPX and S1P induced angiogenesis. 
(a) - (d) 4X phase contrast images show that the inhibitory effects of W146 were 
obvious on CPX and S1P induced angiogenesis.  (e) - (g) Quantifications of skeletal 
length, cell number and maximum sprout length. Attenuation effects of W146 on 
capillary sprouting were clearly seen in terms of shorter skeletal and maximum 
sprout length and reduced cell number despite of the negative effects caused by the 
vehicle control. Scale bar = 100 µm. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001  
 
As S1P1 also plays roles in regulating cell migration, I then quantified the 
endothelial migration in collagen gel on control side(towards empty alginate 
beads). As shown in Figure 5-12, the number of migrating cells and migration 
distance in W146 treated group were reduced to baseline levels which were 
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from 31.5 ± 3.2 to 10.0 ± 1.9 cells and 147 ± 8 to 104 ± 15 µm, respectively, as 
compared to the vehicle control. These results were also in line with the 
quantifications of skeletal length, cell number in sprouts and maximum 
sprout length where the vehicle control group showed reduced cell migration 
but not as significant as W146 treated group. 
 
Figure 5-12 Effects of W146 on endothelial migration. (a) and (b) Quantifications of 
cell number and migration distance. W146 inhibited endothelial cell migration in 3D 
collagen gel scaffold resulting in fewer migrating cells and shorter migration distance 
over 4 day. Error bars denote standard error. * p ≤ 0.05, **** p ≤ 0.0001 
 
In order to test if lower concentration of W146 could also inhibit 
angiogenesis in a dose dependent manner, I then reduced the concentration 
of W146 to 1 µM. However, with lower concentration of W146, I were unable 
to achieve significant inhibition on angiogenesis based on the skeletal length 
of capillary sprouts (see Figure 5-13(e)). Nevertheless, I observed changes in 
morphologies of sprouts which were similar to Avastin inhibition where 
diameter of capillary sprouts increased. Moreover, the ends of capillary 
sprouts where tip cells usually extend their filopodia were blunted in most of 
the cases as compared to the vehicle control group (see Figure 5-13(b) and 
(d)). These phenomena were more prominent when I reduced the 
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concentration of W146 from 10 µM to 1 µM as 10 µM of W146 almost 
abrogated the angiogenic events completely which made the observation of 
sprouting behavior become more challenging. I then quantified the diameter 
of capillary sprouts and I showed that with 1 µM of W146, the diameter of 
sprouts increased by 91 % or increased from 15.5 ± 0.3 to 29.7 ± 2.3 µm as 
compared to the vehicle control. Nevertheless, the diameters between non-
W146 treated groups were similar. With these results, I have demonstrated 
that W146 not only inhibits angiogenesis but also changes the morphologies 




Figure 5-13 W146 increases diameter of sprouts. 4x phase contrast images of CPX + 
S1P induced capillary sprouting in microfluidics with (a) 1 µM W146 or (c) equal 
volume of vehicle. (b) and (d) Magnified images of specified areas (marked by red 
and green rectangles) in (a) and (c) respectively that show the detailed morphologies 
of sprouts in collagen gel. Some sprouts were out of focus because they were 
growing across different depths in 3D collagen gel. Quantifications of (e) skeletal 
length and (f) diameter of sprouts under the effects of CPX + S1P, CPX + S1P + 1 µM 
W146 and CPX + S1P + vehicle in culture media. W146 at concentration of 1 µM did 
not cause significant reduction in skeletal length but the diameter of sprouts was 
increased by 91 % as compared to the vehicle control group. The diameters of 
sprouts between non-W146 treated groups were not significantly different. Scale 




5.9 Endothelial cell CM increases MCP-1 secretion 
by IMR90 
I have shown the pro-angiogenic effects of CPX and S1P in combination and 
these improvements to capillary sprouting were more significant if fibroblasts 
were present. Therefore, I continued the studies to investigate the possible 
interaction between endothelia and fibroblasts that is important in 
angiogenesis. To study the influence of endothelial cells on fibroblasts, I 
cultured IMR90 cells in EC CM with or without the addition of CPX+ S1P and 
quantified factors secreted by fibroblasts by proteomic profiler and ELISA. 
Among the 55 angiogenesis related proteins that the proteomic profiler can 
detect, MCP-1 was the only cytokine derived from fibroblasts that showed 
significant change when treated with EC CM. Interestingly, MCP-1 has also 
been reported to play a role in promoting angiogenesis through VEGF 
pathway [158]. To further validate the results, I did ELISA to measure the 
concentration of MCP-1 quantitatively. I detected a basal secretion level of 
2450 ± 511 pg/ml-Million cell-day in fibroblasts culture. Endothelial cell CM 
induced the secretion of MCP-1 by fibroblasts by 3-fold in the absence of any 
CPX + S1P induction, however, the combination of both pharmacological 
agents increased MCP-1 secretion by a further 39%. As monosubstances, 
neither S1P nor CPX were able to increase basal MCP-1 secretion. However, 
MCP-1 secretion by EC was downregulated by CPX + S1P, from 1695 ± 32.8 to 
955 ± 62.2 pg/ml-Million cell-day (Figure 5-14).  
Previously, endothelin-1 and EGF have been shown to activate fibroblasts to 
secrete higher level of MCP-1 [159, 160]. Interestingly, CPX + S1P 
combination was able to upregulate endothelin-1 and EGF expressions by EC 
but did not show similar effects on fibroblasts culture. Instead, endothelin-1 
and EGF level measured from fibroblasts cultured in EC CM showed values 
lower than the basal levels. These indicated either cellular uptake (taken by 




Figure 5-14 Endothelial CM modulates growth factor secretion by fibroblasts. (a) 
ELISA: fibroblasts secrete 3 times more MCP-1 when cultured in EC CM. No 
significant difference in MCP-1 secretion is elicited by CPX or S1P in fibroblasts 
culture. (b) and (c): semi-quantitative proteomic array plots showing clearance of EC 
secreted endothelin-1 and EGF from culture media in the presence of fibroblasts 
suggestive of either cellular uptake or degradation of measured target proteins . * p 
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001   
 
5.10 Diffusion profiles of VEGF and PlGF in 
fibroblast populated devices  
The presence of fibroblasts was indispensable in the system as shown earlier 
although they were kept separated from endothelial cells by collagen gel 
where soluble factors are able to diffuse through. Therefore, I hypothesized 
that soluble factors derived from endothelia and fibroblasts play important 
role in CPX + S1P induced angiogenesis. This hypothesis has been supported 
by the proteomic profiling data where I detected the upregulations of 
different sets of angiogenic cytokines from endothelia and fibroblasts when 
they were treated with CPX. Most importantly, fibroblasts not only 
responded to the stimulation of CPX but also to the treatment of EC CM. I 
have shown that the MCP-1 secretion level of fibroblasts was directly 
influenced by endothelial cell CM and this suggests that EC-fibroblast 
communication is important in determining the proteomic secretion profiles 
of each cell type.  
Since endothelia and fibroblasts rely on diffusive factors to communicate in 
microfluidics, I further the studies by employing COMSOL Multiphysics 
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simulation software to study the concentration profiles of secreted protein in 
microfluidic devices. PlGF secreted by EC and VEGF secreted by fibroblasts 
were used as representative proteins. The model was built based on a 2D 
transport of diluted species model. The diffusion coefficients of VEGF and 
PlGF in cell culture media, collagen gel and alginate beads were estimated 
based on a 40 kDa inert molecule from Stokes-Einstein equation and also 
adapted based on previous findings [130, 131]. The secretion and 
consumption rates of VEGF and PlGF were calculated based on the ELISA 
results that I obtained previously and normalized against cell number in 
microfluidics. The initial concentration of VEGF and PlGF was set as 3.198x10-
8 mol/m3 and 0 respectively based on the concentration of these two proteins 
in culture media as determined through ELISA. Modeling showed that the 
concentration gradients of PlGF and VEGF could be maintained across the 
collagen gel after 24 h with concentration gradients of -0.206 pg/ml.µm 
(negative sign denotes the convention of diffusion direction) and 1.07 
pg/ml.µm, respectively (Figure 5-15). These simulations demonstrate that 
soluble growth factors could diffuse through collagen gel and also suggest 
that communication between EC and fibroblasts is bi-directional.  
 
Figure 5-15 COMSOL simulations of growth factor concentration profiles in 
microfluidic devices. 2D concentration heat maps depict the modeled concentration 
profiles of (a) VEGF and (b) PlGF at 24 h. Call out pictures: red lines across the 
collagen gel regions represent the trajectories along which the concentration 
distributions in (c) are calculated. (a) and (b) Concentration heat maps; high 
concentration (red) to low concentration (blue). (c) The mean concentration 




5.11 MCP-1 neutralizing antibody inhibits CPX and 
S1P induced angiogenesis 
Fibroblast-derived MCP-1 has been shown to be upregulated by EC CM. To 
identify its mechanism of action in CPX + S1P induced angiogenesis, the 
spouting assay was repeated with CPX + S1P but with human MCP-1 
neutralizing antibody (anti-MCP-1), AF-279-NA added at 2 µg/ml or with 
addition of 2 µg/ml of IgG as a control in all channels. The presence of anti-
MCP-1 reduced angiogenesis to baseline levels while IgG control showed little 
or no effect. I then quantified the skeletal length of sprouts, number of cells 
and maximum sprout length. Anti-MCP-1 reduced the skeletal length of 
sprouts from 14100 ± 2090 to 6660 ± 963 µm, decreased the cell number 
from 460 ± 83 to 137 ± 25 and shortened the maximum sprout length from 
374 ± 47 to 192 ± 34 µm as compared to the IgG control group.  (Figure 
5-16(e)-(g)). Consequently, I conclude that MCP-1 plays an important role in 








Figure 5-16 MCP-1 neutralizing antibody inhibits CPX and S1P induced angiogenesis. 
(a) - (d) 4X phase contrast images show the inhibitory effects of MCP-1 neutralizing 
antibody (anti-MCP-1) on CPX and S1P induced angiogenesis. Sprout formation was 
inhibited when ECs were treated with 2 µg/ml anti-MCP-1 together with CPX and 
S1P stimulation.  EC treated with 2 µg/ml IgG and CPX + S1P formed extensive 
sprouts that were similar to the positive control where CPX + S1P was used to 
stimulate angiogenesis.  (e) - (g) Quantifications of skeletal length, cell number and 
maximum sprout length. Anti-MCP-1 effectively attenuated the angiogenic events 
that were induced by CPX + S1P as reflected by significantly shorter skeletons, fewer 





5.12 Conditioned medium of IMR-90 induces non-
directional sprouting 
Based on the results that suggested the soluble factors derived from 
endothelia would influence the proteomic secretion profiles of fibroblasts, I 
hypothesized that the interactions between endothelia and fibroblasts were 
important to CPX + S1P enhanced angiogenesis. In order to confirm this 
hypothesis, conditioned medium (CM) from fibroblast culture that received 
no inducement factors from endothelia was collected  and then circulated 
through microfluidic devices that were seeded with endothelial cells. 
Fibroblast CM was able to induce angiogenesis, but with less intensity. In 
addition, the sprouts formed under the induction of fibroblast CM were less 
organized as compared to the sprouts formed in fibroblast-seeded devices. 
The fibroblast CM-induced sprouts also invaded into the collagen collectively 
and failed to form a distinct vascular network structure. Furthermore, 
confocal images also showed that the VE-cadherin staining in CM-induced 
sprouts was more diffuse in contrast to the crisp and clear VE-cadherin 
staining in the sprouts formed in fibroblast-seeded devices (Figure 5-17(b)). 
The high density of CM-induced sprouts made identification of individual 
sprouts and assessment of skeletal length per unit length difficult. Instead, I 
measured the fluorescent area (of sprouts) per unit length to compare the 
morphologies of sprouts under these two conditions. The area per unit length 
of sprouts in the CM treated group was 135 % larger or increased from 89.9 ± 





Figure 5-17 Fibroblast conditioned medium induces sprouts that are less organized. 
(a) 4x phase contrast images: fibroblast CM- induced sprouting (right) differed from 
those seen in EC-fibroblast co-culture (left) under induction of CPX + S1P.  Fibroblast 
CM did induce sprout formations but they were  in a collective migration pattern 
rather than distinct  vascular network formation as seen in fibroblast-seeded devices. 
(b) 20 X confocal images of Hoechst stained nuclei (blue) and Alexa fluor 488 
immunostained VE-cadherin (green): fibroblast CM induced sprouts showed diffuse 
cytoplasmic VE-cadherin staining pattern in contrast to crisp and clear pericellular 
VE-cadherin staining in fibroblast-seeded control group (c) quantitative comparison 
between fibroblast-seeded control group (fibroblasts seeded devices) and fibroblast 
CM treated group (conditioned medium). Area of sprouts were normalized against 
maximum sprout length to approximate the complexity and tortuosity of the sprouts 
formed. Scale bar = 100 µm.  **** p ≤ 0.0001 
 
5.13 Effects of A549 lung carcinoma epithelial cells 
on endothelial sprouting 
As I have shown earlier, fibroblasts are important in mediating CPX + S1P 
induced angiogenesis. I then asked if these effects were specific to endothelia 
and fibroblast co-culture. Since A549 lung carcinoma epithelial cells have 
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been shown to promote angiogenesis through secretion of VEGF and this 
secretion can also be further boosted by treatment of PHi [161, 162], I used 
A549 lung carcinoma as mediating cell type to substitute the roles of 
fibroblasts. Lung carcinomas were encapsulated by alginate beads with 
identical two-phase microfluidic method and same cell concentration as used 
in fibroblast encapsulation. As shown in Figure 5-18(b), A549 lung carcinoma 
epithelial cells can be encapsulated with homogeneous cell distribution due 
to their less adherent nature as compared to fibroblast. Similar to previous 
experiments, CPX + S1P combination was applied in all channels to induce 
angiogenesis. Based on Figure 5-18(c)-(f), I could compare the capillary 
sprouting between EC-lung carcinoma and EC-fibroblast co-cultures 
qualitatively where EC-lung carcinoma co-culture resulted in reduced density 
of sprouts in collagen gel (towards cell encapsulated beads) and the sprouts 
tended to detach from endothelial monolayer after 4 day as compared to EC-
fibroblast co-culture. In addition, sprouts between adjacent posts did not 
anastomose as readily in EC- co-culture. Therefore, I have shown  that not all 
cell types possess the same potential to induce sprouting, and even in a 




Figure 5-18 Endothelia-lung carcinoma co-culture induces sparser capillary sprouting 
as compared to the endothelia-fibroblast co-culture under the induction of CPX + 
S1P. (a) Schematic diagram of the microfluidic device used. (b) 4x phase contrast 
images of A549 lung carcinoma epithelial cells encapsulated alginate beads in right 
channel. CPX + S1P induced capillary sprouting in microfluidics with encapsulated (c) 
A549 lung carcinoma epithelial cells or (e) fibroblasts as mediating cells. (d) and (f) 
Magnified images of specified areas (marked by red and yellow rectangles) in (c) and 
(e) respectively that showed the detailed morphologies of sprouts in collagen gel. 
EC-lung carcinoma co-culture elicited capillary sprouting with different sprouts 
morphologies as compared to EC-fibroblast co-culture under induction of CPX + S1P. 





 CHAPTER 6. DISCUSSION 
 
There is strong evidence from the literature that both S1P and HIF-1 are 
important for angiogenesis, however, it has remained unclear which of the 
two factors dominates in a regulatory hierarchy [111, 112, 163, 164]. Anelli et 
al. have shown that hypoxia can upregulate the expression of Sphk1, an 
enzyme that phosphorylates sphingosine into S1P [111]. In addition, Ader et 
al. showed that Sphk1 can stabilize HIF-1α through Akt/glycogen synthase 
kinase-3β pathway [163]. Therefore, it is possible that S1P and hypoxia can 
form a feed-forward amplification loop to augment the angiogenic effects of 
both hypoxia and S1P. In addition, VEGF, a growth factor that is upregulated 
in hypoxia, has been shown to mediate S1P induced angiogenesis [7]. This 
finding further supports the hypothesis that hypoxia and S1P can together 
exert greater proangiogenic effects. As both factors have been considered in 
isolation I set out to study the interplay between S1P and HIF-1 in a co-
culture system to predict their utility for neovascularization approaches in 
regenerative medicine. In order to modulate HIF-1 activity, I employed prolyl 
hydroxylase inhibitors (PHis) that could prevent the degradation of HIF-1α, a 
subunit of HIF-1 that would otherwise be degraded rapidly under normoxia 
[48]. Among the three PHis tested, CPX showed the greatest angiogenic 
potential while PDCA could only induce little to no sprout formation. The pro-
angiogenic performance of HDZ lay between CPX and PDCA. Interestingly, 
addition of S1P did not increase formation of capillaries in the PDCA treated 
group but addition of S1P further boosted the angiogenic potentials of both 
HDZ and CPX in the same context. The different angiogenic effects of PHis 
might be due to the different regulating mechanisms as PDCA is a 2-
oxoglutarate (2-OG) analog while HDZ and CPX are iron chelators [4, 63, 80]. 
As reported earlier, 2,4-pyridine dicarboxylate (PDCA) and 2,5-pyridine 
dicarboxylate are both 2-OG anologs with similar structures but they bind 
differently to the  prolyl hydroxylase domains (PHD) 1, PHD2 and PHD3 of 
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HIF-1α [165]. Therefore, the respective binding affinities and specificities of 
HDZ and CPX to PHD isoforms can be very different even though they are 
both iron chelators. As a consequence, their abilities to induce angiogenesis 
in in vitro microfluidics are different. Since CPX showed the greatest potential 
in inducing angiogenesis in microfluidics, I therefore combined S1P with CPX 
to maximize the angiogenic effects in the following studies. 
I teamed endothelial cells up with fibroblasts, as the latter cell type is 
abundantly present in almost every tissue, and as it has been shown to 
produce angiogenic factors to stabilize vessel formations and these effects 
can be further augmented in the presence of PHis [4, 166, 167]. IMR-90 
human lung fibroblasts were chosen for current study as our group has 
previously shown that IMR-90 respond to PHi stimulations by upregulating 
VEGF secretion to mediate angiogenesis. As observed, the immature sprouts 
that formed in collagen gel scaffold can grow into a more developed capillary 
network only if fibroblasts were present which reflects their importance in a 
microfluidic setting. In order to focus on the angiogenic effects of fibroblast-
secreted growth factors, I kept both cell types physically separate; through 
alginate beads encapsulation technique, to generate soluble factor gradients 
while preventing juxtracrine signaling. Kim et al. showed that the viability of 
fibroblasts was not affected by alginate encapsulation [9]. In addition, Kim et 
al and Keshaw et al both showed that the encapsulation of fibroblasts with 
alginate did not impede the VEGF production from fibroblasts and the 
encapsulated fibroblasts were also shown to be pro-angiogenic [9, 168]. 
Furthermore, Shoichet et al. also showed that proteins with various sizes can 
diffuse through alginate gels with a diffusion coefficient close to diffusion in 
water [169]. While alginate does not affect the viability and angiogenic 
potential of fibroblasts, alginate itself does not presence in in vivo. With 
alginate encapsulation, fibroblasts cluster within the core of alginate beads 
and this change of microenvironment might affect the fibroblast-derived 
secretomes. Kankuri et al. showed that hepatocyte growth factor was 
upregulated by more than 200 fold in fibroblast clusters as compared to 
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monolayer culture [170]. I understand that both encapsulated fibroblasts and 
fibroblasts in monolayer culture are not able to replicate the in vivo 
conditions perfectly but the encapsulation technique allows us to achieve a 4 
to 1 ratio of fibroblast to EC that is more physiologically relevant. Besides, it 
also allows us to study the paracrine effects of fibroblasts in angiogenesis in a 
controlled way where most of the fibroblasts do not invade into collagen and 
this prevents the collapse of collagen due to the fibroblast contraction. 
Nevertheless, the strength of alginate will decrease over time especially if 
cells are encapsulated as shown by Shoichet et al. [169]. Therefore, some of 
the encapsulated fibroblasts broke free from the alginate beads after 4 days 
of culture and a few of those invaded into the collagen gel. Invasion of 
fibroblasts into collagen gel will lead to collagen gel remodelling which results 
in matrix contraction [171]. In addition, Velazquez et al. also showed that the 
presence of fibroblasts in close proximity to endothelial cells promoted the 
formation of vascular network in an in vitro collagen sandwich assay [172]. 
Consequently, I do not rule out the possibility that fibroblasts might exert 
pro-angiogenic effects when they are in close contact to endothelial cell. 
Nonetheless, the number of fibroblasts that successfully invaded into the 
collagen region was limited and usually less than 10 cells per device (Figure 
5-3 and Figure 5-4) as compared to 100 k fibroblasts in the side channel.  As a 
consequence, the paracrine effects exerted by alginate encapsulated 
fibroblasts are the main effects that I am looking into.  
I showed that the presence of fibroblasts in the devices was indispensable in 
generating a sprouting response, spontaneously and in the presence of the 
compounds. However, the combination of CPX + S1P yielded a surprisingly 
extensive formation of a highly complex vascular network with lumina within 
4 days that almost completely traversed the 1.25 mm collagen gel region. 
Hence , this combination held the promise to be used to develop capillaries 
into fully functional network in a relatively short time and this would be 
especially beneficial for therapeutic angiogenesis. The angiogenic potential of 
CPX + S1P can only be shown in an EC and fibroblast co-culture context.  
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Conventional in vitro assay such as Matrigel assay is usually not suitable for 
the studies involved co-culture with nonendothelial origin such as fibroblasts 
that may respond to Matrigel and form cords [135]. While the Transwell 
assay is suitable for co-culture assay, it can only study the endothelial 
migration; which is only a step of the complicated angiogenesis processes.  In 
addition, the generation and control of solute concentrations can be done in 
the microfluidic assay. The importance of VEGF gradient was demonstrated 
by Gerhardt et al.  that directed tip cell migration is dependent on a VEGF 
gradient in the rat aortic ring and retina development assays [146]. 
Furthermore, the microfluidic approach also allows us to focus on the 
paracrine effects between EC and fibroblasts under the induction of CPX + 
S1P where some other conventional assays may not be able to do so such as 
Matrigel assay. Nevertheless, I still need to rely on other biochemistry assays 
such as ELISA and proteomic analysis membrane to determine the specific 
angiogenic proteins that are relevant in CPX + S1P induced angiogenesis. 
While I understand that a microfluidic platform is not a single solution for all 
questions that need to be answered in angiogenesis, the microfluidic 
platform acts as a functional assay to study closely on how CPX + S1P can 
affect the formation and morphogenesis of angiogenesis in 3D in the 
presence of fibroblasts, which is otherwise unobtainable with Matrigel or 
Transwell assays. With this microfluidic platform, I successfully recapitulated 
the endothelial migration, proliferation, lumen formation and sprouts 
anastomosis which are key steps in in vivo angiogenesis [173]. Furthermore, I 
also clearly showed that VE-cadherin that is important in vascular 
permeability, endothelial survival and lumen formation distributes 
predominantly at intercellular junctions and this further confirms that the 




6.1 CPX induced differential expressions of 
angiogenic proteins from both endothelia and 
fibroblasts 
While the combination of S1P and CPX showed a clear morphological 
advantage over the single use of either compound, CPX seemed to be the key 
component in augmenting the secretion of various angiogenic factors. In 
addition, endothelia and fibroblasts obviously responded to CPX with a 
different repertoire of angiogenic growth factors. This ties in with earlier 
findings where different mesenchymal cell types were induced to 
overexpress HIF-1 and different cell types showed the increases of different 
angiogenic growth factors [51]. In the experimental system, human fetal lung 
fibroblasts mainly secreted HGF, IGFBP-2, uPA and VEGF under the influence 
of CPX (Figure 5-5). This is coherent with previous reports showing 
stabilization or upregulation of these proteins or their mRNA under hypoxic 
conditions [51, 56, 57, 60]. Since the discovery of VEGF in 1980s, VEGF has 
quickly been recognized as one of the most potent growth factors with 
pleiotropic functions in driving angiogenesis [175]. While HGF regulates 
endothelial cell growth and survival, IGFBP-2 enhances VEGF production and 
uPA participates in the degradation of ECM which then facilitates the release 
of matrix-bound growth factors and enhances cell motility [176-180].  Among 
these, HGF has been shown to be released from fibroblasts in EC-fibroblast 
co-culture and the inhibition of HGF would greatly reduce angiogenesis [22, 
23, 181]. The secretion of these proteins in fibroblasts can be further boosted 
by CPX which also verifies the importance of fibroblasts as mediating cells in 
the system.   
In contrast, endothelial cells showed an upregulation of PlGF, endothelin-1, 
EGF and IL-8 (Figure 5-5). This is highly significant, since at least five different 
synergistic angiogenic effects of PlGF with VEGF have been proposed [182]. 
There is currently only one report on the effects of PHi using L-mimosine in a 
model of a thrombosed vena cava on increased PlGF present  in the vessel 
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wall, but the cell source for PlGF was not established [183]. The chemokine 
IL-8 has been implicated in promoting angiogenesis by enhancing EC 
proliferation and migration via autocrine signaling [184]. Hypoxia has been 
reported to increase the secretion of IL-8 chemokine in in vitro endothelial 
cultures through the activation of HIF-1α [58]. Hirata et al. and Sun et al. have 
shown that downregulation of EGF receptor could effectively block 
angiogenesis in vitro and these findings also confirm the pro-angiogenic role 
of EGF [185, 186]. As reviewed by Knowles et al., ET-1 enhances angiogenesis 
through multiple pathways including direct stimulation of HUVEC 
proliferation, migration and invasion, increase production of VEGF and also 
activation of fibroblasts that helps matrix remodeling [187].  
Apart from those 8 cytokines that were significantly upregulated in 
endothelial or fibroblast cultures by CPX or CPX + S1P, other angiogenesis 
related proteins that have been reported to favor or oppose angiogenesis 
were detected in the proteomic profiling assay too. Amphiregulin, IGFBP3 
and PEDF were the three proteins only found in fibroblast culture. 
Amphiregulin, which is a ligand for EGFR, could help promote angiogenesis 
through increasing the expressions of MMP-2 and MMP-9 [188]. IGFBP3 
could increase the vascular survival and regrowth after oxygen-induced 
vasoobliteration in mice retina [189]. In contrast, PEDF is a potent angiogenic 
inhibitor that blocks neo-vessel formation in rat corneal model under 
normoxia [190]. Several other proteins have also been detected in both 
endothelial and fibroblast cultures including endostatin, PTX3, PAI-1, TIMP-1 
and thrombospondin-1. Among these, PAI-1 is the only protein that has been 
reported to be pro-angiogenic but the rest of the group are known inhibitors 
of angiogenesis [191-195]. It is logical that cells, especially endothelia would 
secrete inhibitors of angiogenesis to maintain the quiescent state of 
endothelium during non-pathological or normoxic conditions. All of the 
proteins that were upregulated by CPX as mentioned earlier are indeed pro-
angiogenic but the levels of anti-angiogenic proteins remained unchanged 
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when treated with CPX. This explains the increased angiogenesis as induced 
by CPX which mimics a hypoxic condition in microfluidics. 
To further confirm the increase of pro-angiogenic proteins is indeed the 
reason for the enhanced angiogenesis, inhibitors that are specific to the 
secreted proteins or their respective receptors were used. VEGF secreted by 
fibroblasts and EGF secreted by endothelia were chosen for the inhibitor 
studies as VEGF is a key angiogenic factor that regulates multiple 
angiogenesis related activities. In addition, only EGF secretion was further 
boosted by CPX + S1P as compared to CPX alone (Figure 5-5 (c) ). 
The VEGF ligand inhibitor, Avastin could inhibit the angiogenesis induced by 
CPX + S1P and brought it back to baseline levels that were similar to the 
culture media control (Figure 5-6). Interestingly, the diameter of capillary 
sprouts also increased significantly in the Avastin treated group as compared 
to the IgG control group (Figure 5-7). Previous findings have indicated that 
diameter of sprouts grown in vitro is affected by different VEGF isoforms and 
VEGF concentrations where VEGF189 reduces vessel diameter while VEGF165 
and VEGF121 lead to increased vessel diameter in a concentration dependent 
manner [150, 196]. The ELISA assay primarily detects VEGF165 and VEGF165b, 
hence I cannot rule out the possibility that splice variants different from 
VEGF165 are present and exert angiogenic effects in the system. Nonetheless, 
it is surprising to observe larger sprout diameter in the presence of Avastin as 
Avastin neutralizes every splice form of human VEGF including VEGF165 that 
increases vessel diameter [197]. However, the previous findings were done 
based on exogenously added recombinant VEGF in the presence of skin 
fibroblasts but not with inhibition or interference of VEGF [150]. Hence, the 
results indicate the possibility of a biphasic behavior of sprout diameter in 
response to VEGF concentration. Besides, I also showed that the lumen 
formation in capillary sprouts were not affected by Avastin although VEGF 
has been suggested to help lumen formation in previous study [198]. 
EGFR inhibitor, Gefitinib was ineffective in inhibiting angiogenesis in the 
settings (Figure 5-8). This is an unexpected observation although previous 
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findings have shown that EGF could induce angiogenesis in mouse corneal 
model [185, 199]. Nevertheless, researchers from the same group also 
showed that EGFR inhibitors, Iressa and Gefitinib could only attenuate EGF 
induced angiogenesis but not VEGF induced angiogenesis. As elevated 
secretion of VEGF from fibroblasts is expected when CPX + S1P is introduced, 
this might be the reason why Gefitinib is ineffective in attenuating the 
angiogenesis induced by CPX + S1P in the presence of fibroblasts. The VEGF 
and EGFR inhibitor studies demonstrate that the growth factors secreted by 
fibroblasts in response to CPX + S1P treatment, such as VEGF, definitely play 
a critical role in angiogenesis but single inhibitor would not be sufficient for 
total inhibition due to the complex nature of sprout formation and the 
involvement of multiple chemokines in modulating angiogenesis. 
 
6.2 S1P induced EC migration and angiogenesis is 
S1P1 dependent 
All soluble factors chosen for analysis, some of which showed significant 
upregulation in the presence of CPX, remained unchanged in the presence of 
S1P. I therefore asked what could be the role of S1P in a PHi induced 
angiogenesis model? S1P is known to induce endothelial migration which is 
also a key process during angiogenesis [90, 155]. The immature sprouts that 
invaded into collagen gel on control side (towards empty alginate beads) 
usually converted to single cell migration on day 4 which offered an excellent 
platform for quantifying the effects of S1P on endothelial migration. The 
increased cell migration in the S1P and CPX + S1P treated groups were 
confirmed based on the increased number of migrating cell and migration 
distance in collagen gel as compared to the CPX treated group and the 
culture media control (Figure 5-9). This suggests that endothelial migration, 
which is a key step in angiogenesis, can only be enhanced by S1P but not by 
CPX in a microfluidic setting.  
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Among the five G-protein coupled receptors S1P1 to S1P5, S1P1 and S1P3 have 
been associated with S1P induced cell migration and angiogenesis [16, 98, 99]. 
I showed that the endothelial cells that I used did express S1P1 under 
different pharmacological treatments. Surprisingly, I observed increased S1P1 
expression in the CPX treated, S1P treated and CPX + S1P treated groups. 
Since the CPX + S1P combination did not further increase S1P1 expression as 
compared to the CPX monosubstance  or S1P monosubstance treated groups, 
the combined angiogenic effects induced by CPX + S1P remains unclear at 
this point. A plausible explanation can be derived from the observation that 
VEGF increases the amount of S1P1 receptor on endothelial cells in a dose-
dependent manner [7]. In a co-culture system therefore the CPX-induced 
factors such as VEGF from fibroblasts could enhance the sensitivity of 
endothelial cells to S1P, which, via the Rho family GTPase Rac activation, then 
would  induce cell migration, tube formation and increase the integrity of the 
endothelial barrier (Figure 6-1) [6, 100]. 
To further test the importance of S1P1 in CPX + S1P induced angiogenesis, I 
then probed the culture system with a S1P1 inhibitor, W146, sprouting was 
brought down to baseline levels (Figure 5-11). Similar findings in a rabbit 
cornea model have been reported where VEGF-induced angiogenesis is 
inhibited with a novel specific S1P1 blocker [101]. However, I also observed 
reduced angiogenic sprouting in the ethanol vehicle control group. The 
inhibitory effects of ethanol were confirmed in previous findings that acute 
ethanol exposure would impair angiogenesis in a scald burn wound model in 
mice [200]. Nonetheless, there was significant difference between the W146 
treated group and the vehicle control group as reflected by fewer and shorter 
capillary sprouts in collagen gel. As discussed earlier, S1P1 involves in S1P 
induced cell migration and this is once again confirmed in the assay where I 
show that W146 not only reduced the number of migrating cells but also the 
migration distance in collagen gel on control side (towards empty alginate 
beads) as compared to the vehicle control group (Figure 5-12).  
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Since the use of ethanol as vehicle exerted certain inhibitory effects, I then 
reduced the concentration of W146 so did volume of ethanol by 10 times to 
test if a lower concentration of W146 was still effective in inhibiting 
angiogenesis. At lower concentration, I were unable to obtain statistical 
significance in the metrics that I used to quantify angiogenesis as compared 
to the control groups (Figure 5-7). Nonetheless, I observed a 91 % increase of 
sprout diameter in the W146 treated group. Previous findings show that 
inhibition of S1P3 alone by a S1P3 specific inhibitor, VPC01091, increases both 
arteriolar and venular diameters as compared to the scaffold control in a 
dorsal skinfold window chamber assay on mice [201]. As S1P1 and S1P3 work 
hand in hand in S1P induced angiogenesis, the increased diameter of sprouts 
caused by S1P1 inhibition further confirms this observation. The W146 
inhibition was similar to Avastin inhibition where diameter of sprouts in both 
cases increased. However, they were also different from the aspect that 
W146 almost blunted the capillary sprouts and led to the disappearance of 
filopodia, which was an indication of the loss of tip cells [202]. Although 
previous findings have suggested that tip cell formation and migration are 
related to VEGF gradient, yet I have found that S1P1 inhibition was more 
effective than VEGF inhibition in reducing tip cell formation [146]. The S1P1 
inhibitor studies not only confirm the importance of S1P1 in S1P induced cell 
migration but also show that S1P1 can modulate the morphologies of 
capillary sprouts. 
 
6.3 Interactions between EC and fibroblasts are 
important in CPX+S1P induced angiogenesis 
I have thus far shown that CPX and S1P each play a different role in CPX + S1P 
induced angiogenesis and the presence of fibroblasts is a prerequisite for the 
angiogenic effects to occur. Previous findings have confirmed that the pro-
angiogenic potential of fibroblasts is acted through secretion of cytokines but 
this study is the first that investigates the fibroblast and EC cytokine profiles 
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under CPX, S1P or CPX + S1P inductions [21, 22, 166, 203]. In addition, only a 
few studies focus on the effects of EC derived factors on fibroblasts. EC CM 
has been shown to induce fibroblast proliferation while EC CM collected  
post-hypoxia treatment induced the migration of fibroblasts in a ET-1 and 
PDGF dependent manner [204, 205]. Previous findings also suggest that EC 
and fibroblast interactions are dependent on ET-1 mediated activation of 
fibroblasts which then enhance angiogenesis [25]. In addition to ET-1, EGF is 
another growth factor that has been shown to be capable of activating 
fibroblasts [206, 207]. Activated fibroblasts are known to secrete more 
angiogenic growth factors including HGF and FGF but more intriguingly, 
activated fibroblasts would also secrete MCP-1, a key chemokine in 
regulating migration, filtration and recruitment of monocytes/macrophages 
that play important roles in promoting aniogenesis [208-210]. Therefore, the 
upregulation of ET-1 and EGF in endothelia culture as induced by CPX + S1P 
suggests that they might have potential roles in mediating endothelia-
fibroblast interactions. Moreover, the levels of ET-1 and EGF measured from 
fibroblasts that were cultured in the EC CM were reduced as compared to the 
baseline levels which also implied either cellular uptake by fibroblasts or 
degradation of these two proteins. Interestingly, I also found that MCP-1 
secretion by fibroblasts was dramatically increased by EC CM treatment but  
was only marginally increased by the combination of CPX + S1P (Figure 5-14). 
Previously, the MCP-1 expression in the skin fibroblasts harvested from 
diabetic patients has been shown to be increased by exogenously added ET-1 
[159]. Similarly, EGF has also been shown to induce expression of MCP-1 in 
synovial fibroblasts [160]. The finite element simulation coupled with the 
fluorescent-dextran assay also showed that the secretomes derived from 
either endothelia or fibroblasts can diffuse through the collagen and reach 
the other cell type. Therefore, the communications between endothelia and 
fibroblasts are not impeded in microfluidics. These findings strongly suggest 
that ET-1 and EGF secreted by endothelia potentially enhanced the MCP-1 
secretion in fibroblasts.  
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MCP-1 has long been associated with inflammatory response, a concomitant, 
if not indispensable mechanism to spur neoangiogenesis [27]. The active role 
of endothelial cells in this inflammatory response has been defined in 
increasing detail recently [29, 211, 212]. MCP-1 has been reported to induce 
angiogenesis by activating the VEGF-A pathway and recruiting mural cells 
[158, 213]. To further confirm the angiogenic effects of MCP-1 and to 
understand its mechanism of action, I employed neutralizing antibody against 
MCP-1 which brought down the CPX + S1P induced capillary sprouting to 
baseline levels as compared to the corresponding IgG control (Figure 5-16). 
Here I show for the first time in microfluidic settings that fibroblast-derived 
MCP-1 induces sprouting as a consequence of fibroblast activation through 
endothelial factors. 
To confirm the importance of endothelia-fibroblast crosstalk, I tested the 
efficacy of fibroblast CM in inducing angiogenesis. The CM of fibroblasts 
induced capillary sprouting events and this demonstrated that secretomes 
derived from fibroblasts did promote angiogenesis. Nonetheless, the 
morphologies of sprouts formed as induced by fibroblasts CM were different 
from sprouts seen in fibroblast populated devices where CM induced sprouts 
were more irregular with less directional extension. More often, the sprouts 
invaded into the collagen gel in a collective manner which also rendered the 
identification of single sprout or capillary network much more difficult. Based 
on confocal images, I could observe that VE-cadherin that was supposed to 
localize around intercellular junctions was more diffuse in cytoplasm which 
suggested that the integrity of the sprouts such as permeability was 
compromised [214]. The tortuous and unorganized morphologies together 
with diffuse VE-cadherin showed that the CM induced capillary sprouting 
events were poorly regulated just like the tumor vasculatures [215].  
Another facet to consider is the loss of angiogenic proteins during sample 
processing. Although the CM collected from the fibroblasts was used 
immediately for culturing EC to minimize protein denaturation caused by 
freeze and thaw cycles, some of the proteins or signalling molecules may lose 
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in the dialysis process. Wang et al. showed that the production of nitric oxide 
(NO) was not exclusive to EC and immune cells as human dermal fibroblasts 
can produce  NO too [216]. It was very likely that fibroblast derived NO would 
pass through the membrane and lost in the dialysis process due to its small 
size. Furthermore, NO has a very short half-life of 20 min in aqueous solution 
which was shorter than the time required for sample preparation [217]. The 
possible loss of NO might explain the discrepancy between the results 
obtained from conditioned media experiments and the microfluidic 
experiment as nitric oxide is a key player with multi-factorial effects in 
angiogenesis including increase of EC survival and proliferation and induction 
of the EC derived bFGF autocrine loop [218]. Unfortunately, the dialysis step 
was required to concentrate the conditioned medium to the level that was 
comparable to the concentration in microfluidic assay. The high density cell 
culture cannot be achieved in a 2D well plate culture as the evaporation of 
media caused the cell death. With these, I further confirm that the 
communication between endothelia and fibroblasts is dependent on 
paracrine signaling and these interactions are important in modulating 
sprouting behavior and cannot be replaced by fibroblast CM. 
The enhanced angiogenesis induced by CPX + S1P relies on interactions 
between endothelia and fibroblasts and I asked if these angiogenic effects 
can take place in EC co-culture with another cell type. A549 lung carcinoma 
epithelial cells have been shown to induce angiogenesis through secretion of 
VEGF and bFGF in a dorsal mice air sac model [161]. Furthermore, the 
expression of VEGF in A549 culture is upregulated by hypoxia and PHi 
treatments [162]. Nonetheless, I did not observe extensive angiogenic 
response in endothelia-lung carcinoma co-culture model even when the cells 
were induced by CPX + S1P. The capillaries formed with A549 lung carcinoma 
epithelial cells as mediating cells were sparser and less developed as 
compared to those formed in fibroblast populated devices. This might due to 
the fact that A549 lung carcinoma epithelial cells are of epithelial lineage 
while fibroblasts are of mesenchymal lineage [219]. Nevertheless, A549 lung 
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carcinoma epithelial cells remained encapsulated in the alginate capsules but 
some fibroblasts would break free from the alginate beads after 4 days of 
culture. Although the diffusion coefficients of proteins in media and in 
alginate layers are very similar, the closer proximity of some fibroblasts to the 
endothelial cells might enhance the angiogenic response as compared to 
encapsulated A549 lung carcinoma epithelial cells [169].  
 
 
Figure 6-1 Schematic diagram of PHi + S1P-driven capillary sprouting. PHi exerts 
differential effects on EC and fibroblasts that lead to upregulation of PlGF, IL-8, EGF 
and ET-1 from EC and upregulation of VEGF, HGF, IGFBP-2 and uPA from fibroblasts. 
The soluble factors secreted by fibroblasts together with S1P promote angiogenesis. 
Fibroblasts-derived MCP-1 is induced by endothelial factors and it also supports the 
growth of capillaries   
 
In conclusion, I have characterized a novel, powerful combination of CPX, a 
HIF-1α inducer, and S1P, a Rac signalling activator, for therapeutic 
angiogenesis. The efficacy of this combination is based on the 
pharmacological induction of a physicological crosstalk of endothelia and 
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fibroblasts that occurs in angiogenesis and emulates a wound healing 
response. 
 
6.4 Limitations of current work 
Although the sprouting network formed in collagen scaffold grew in 3D, the 
quantification metrics: skeletal length and maximum sprout length that I 
used were based on the projected 2D images. Therefore, the length that I 
measured might underestimate the actual sprouting length as projected 2D 
images did not consider the vessel length that spanned across different depth 
in collagen gel. Nevertheless, I showed that the sprouting network 
preferentially extended towards fibroblast encapsulated beads as opposed to 
growing vertically up to the PDMS surface or down to the glass substrate 
(Figure 6-2). 
Another limitation of the current work is the lack of systemic approach to 
optimize the concentrations of CPX and S1P as a combination. Although the 
concentrations of CPX and S1P were chosen based on previous studies[4, 
151], the optimum concentrations for these two angiogenic compounds as a 
combination have never been tested. Therefore, the current concentrations 




Figure 6-2 Different angle of views of sprouting network. (a) Top view, (b) side view 
and (c) 45 ° angle view of CPX + S1P induced sprouting network in a microfluidic 
device. Preferentially, the vessels grew towards fibroblast encapsulated beads 





 CHAPTER 7. CONCLUSION AND 
FUTURE WORK 
 
7.1 Contributions of this work 
This thesis has focused on how endothelial sprouting can be 
pharmacologically enhanced by CPX and S1P, and how this enhancement is 
orchestrated via endothelial-fibroblast crosstalk in a microfluidic platform. : 
 the unexpectedly strong angiogenic effects of CPX and sphingosine 1-
phosphate in combination as expressed in morphological 
development of capillary sprouts 
 
 the differential secretion of complementary angiogenic factors by 
either cell type when stimulated with CPX while secretion of other 
anti-angiogenic factors remain unchanged 
 
 the increase of VEGF secretion by fibroblasts as induced by CPX. The 
introduction of VEGF ligand inhibitor, Avastin also suppressed and 
affected morphologies of CPX + S1P induced capillary sprouts 
 
 the effects of S1P in increasing cell motility and  the critical role of S1P 
in this system as a downstream effector and amplifier of signals 
initiated by and associated with HIF-1 stabilization 
 
 the importance of S1P1 in mediating S1P induced endothelial 
migration in microfluidics.  S1P1 also modulates angiogenesis  
whereby the inhibition of S1P1 not only attenuates capillary sprouting 




 the crucial role of endothelia in eliciting MCP-1 secretion from 
fibroblast that is independent of pharmacological stimulation while 
the neutralization of MCP-1 also results in reduction of capillary 
sprouts 
 
 the pro-angiogenic effects of fibroblasts in microfluidics cannot be 
replicated through conditioned medium from fibroblasts or by 
substituting fibroblasts with A549 lung carcinoma epithelial cells 
 
Together, these findings show the possibility of modulating angiogenesis 
through the combination of CPX and S1P in the presence of fibroblasts as 
mediating cells. The effectiveness of this newly proposed strategy relies on 
pharmacological induction of a physiological crosstalk between endothelia 
and fibroblasts that emulates the wound healing response as seen in 
angiogenesis. With the ability to effect multiple angiogenic proteins and also 
the key processes during angiogenesis, this novel vascularization strategy is 
therefore of particular interest for therapeutic angiogenesis. Furthermore, 
this angiogenesis assay also opens up new possibilities not only for 
developing neo-blood vessels in in vitro systems but also for understanding 
the mechanism behind CPX and S1P regulated angiogenesis. The knowledge 
can then be widely applied in various fields including in anti-vascularization 
strategies for cancer research. In conclusion, I believe that I have discovered, 
with the help of a unique microfluidic assay, a therapeutically valuable 
combination of agents to induce tissue repair and regeneration and also 
contributed to the growing knowledge of modulating angiogenesis. 
 
7.2 Future directions 
This work has provided some insights in CPX + S1P induced angiogenesis but 
further work is needed to fully understand its mechanism. Firstly, ligand or 
receptor inhibitions on those proteins that are upregulated by CPX can be 
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performed in a similar way as I did for VEGF and EGFR inhibitions. These 
could help to further confirm which proteins are truly necessary in CPX + S1P 
elicited angiogenesis. Although I have shown that S1P1 is critical in CPX + S1P 
induced angiogenesis, the functions of the other four S1P receptors remain 
unknown. Specific receptor inhibitors can be utilized to further dissect their 
role in angiogenesis, especially for S1P2 and S1P3 that have been suggested to 
play a role in angiogenesis. Besides, the effects of S1P on fibroblasts in these 
setups are yet to be discovered whereby previous findings have shown that 
S1P could affect the collagen deposition and fibroblast chemotaxis in a S1P2 
dependent manner [220, 221]. Also, the interplay between endothelia and 
fibroblasts can be examined more closely by determining if MCP-1 secretion 
from fibroblasts will be affected by downregulation of ET-1 or EGF. 
With the vision to develop a multi-cellular in vitro model that mimics certain 
tissue or organ such as human heart for the better understanding of 
angiogenesis, other cell types can be introduced in the microfluidics that can 
accommodate up to 5 different cells in separate entities. For example, 
cardiac myocytes have been shown to interact with both endothelial cells 
and fibroblasts and these interactions are crucial in angiogenesis in heart [26, 
145, 222, 223]. Consequently, cardiac myocytes can be incorporated into the 
multi-cellular system via cell encapsulation technique or by seeding them into 
the 3D collagen matrix. In addition, importance of mural cells has been 
discussed before and it is clear that pericytes and smooth muscle cells (SMC) 
play pivotal roles in vascular maturation. Hence, seeding of pericytes/SMC in 
the same channel as endothelia could help us further understand their 
functional roles in angiogenesis. 
This model can also be used as a screening platform for both pro- and anti-
angiogenic compounds. For example, perfusable vasculature growing in or 
around a cancer spheroid can serve as an excellent model to study the 
potency of anti-angiogenic compounds in cancer research. As suggested by 
recent study, the endothelia and cancer cell interactions would greatly alter 
the IC50 values of anti-cancer compounds [224]. Similarly, other 
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proangiogenic compounds can be tested in a more physiological relevant 





Appendix A: Comparison between simulated and 
experimental results 
A model was built based on a 2D transport of diluted species model by using 
COMSOL Multiphysics simulation software. The diffusion coefficients of 40 
kDa Texas-red conjugated dextran in cell culture media and collagen gel were 
estimated based on a 40 kDa inert molecule from Stokes-Einstein equation 
and also adapted based on previous findings [130, 132] as summarized in 
Table 4. The initial concentration of 40 kDa dextran was set as 2x10-3 
mol/m3 in the right channel and 0 in every other region based on the 
concentration of 40 kDa that has been added into the microfluidic. As the 
diffusion coefficients for dextran in media and dextran in collagen gel were 
different, the slope of the diffusion profile changed at the two edges of the 
collagen gel and resulted in a sigmoidal diffusion profile. The simulated 
diffusion profile across the collagen gel (in between middle channel and right 
channel) was coherent with the experimental results and confirmed the 
formation of a solute concentration gradient in the microfluidic device.  
 
Figure S1 Comparison between simulated and experimental concentration gradients. 
The dash line represents the simulated concentration gradient obtained from 
COMSOL Multiphysics and the solid line represents the experimental data in a 
microfluidic device. Distance 0 denotes the edge between the middle channel and 
the collagen gel.     
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